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1. Summary 
 
Phosphorylation is a very common posttranslational modification event known to modulate 
a wide range of biological responses. Beyond the regulation of protein activity, the 
interrelation of phosphorylation with other posttranslational mechanisms is responsible for 
the control of diverse signaling pathways. Several observations suggest that 
phosphorylation of poly(ADP-ribose) polymerase-1 (PARP-1) regulates its activity. There 
is also accumulating evidence to suggest the establishment of phosphorylation-dependent 
assembly of PARP-1-associated multi-protein complexes. Although it is relatively 
straightforward to demonstrate phosphorylation of a defined target, identification of the 
actual amino acids involved still represents a technical challenge for many laboratories. 
Using a combination of bioinformatics-based predictions tools for generic and kinase-
specific phosphorylation sites, in vitro phosphorylation assays and mass spectrometry 
analysis, we investigated the phosphorylation profile of PARP-1 and poly(ADP-ribose) 
glycohydrolase (PARG), two major enzymes responsible for poly(ADP-ribose) turnover. 
Mass spectrometry analysis revealed the phosphorylation of several serine/threonine 
residues within important regulatory domains and motifs of both enzymes. Using in vivo 
microirradiation-induced DNA damage, we show that altered phosphorylation at specific 
sites can modify the dynamics of assembly and disassembly of PARP-1 at sites of DNA 
damage. By documenting and annotating a collection of known and newly identified 
phosphorylation sites, this targeted proteomics study significantly advances our 
understanding of the roles of phosphorylation in the regulation of PARP-1 and PARG. 
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2. Introduction 
Poly(ADP-ribose) polymerase-1 (PARP-1) is an enzyme that catalyzes the hydrolysis of 
NAD and the enzymatic transfer of multiple ADP-ribose units to attach poly(ADP-ribose) 
(pADPr) on numerous target proteins, including PARP-1 itself. PARP-1 plays a role in 
major processes involving genomic integrity 1 such as the detection and repair of DNA 
damage 2, chromatin modification 3 as well as replication and transcription mechanisms 4. 
In addition, PARP-1 is involved in cell death signaling pathways 5, 6 making it an attractive 
candidate for potential cancer therapies. The pADPr itself has been shown to be an 
apoptogenic molecule 7, 8. The rapid turnover of pADPr is mediated by poly(ADP-ribose) 
glycohydrolase (PARG), the major cellular pADPr catabolizing enzyme. Although PARP-1 
and PARG have been mostly studied in a context of DNA-damage, chromatin-associated 
functions and apoptosis, there is accumulating evidence that pADPr metabolism is 
important in normal cellular physiology 9-11. 
  
Many studies suggest that PARP-1 activity may be regulated by phosphorylation involving 
several kinases that are parts of important regulatory pathways. Initial in vitro experiments 
indicated that phosphorylation of PARP-1 by protein kinase C (PKC) inhibits its DNA-
binding and polymerase activities 12, 13. Subsequently, in vivo data revealed that PARP-1 is 
phosphorylated following phytohemagglutinin stimulation of resting lymphocytes 14 and 
during Xenopus laevis oocyte maturation 15. More recently, Beckert and collaborators 16 
showed that treatment of endothelial cells with IGF-I resulted in an inhibition of PARP-1 
activity concomitantly with its phosphorylation. Because activation of the extracellular 
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signal-regulated kinases 1 and 2 (Erk1/2) pathway is a major effector in response to IGF-I 
binding its receptor 17, it is tempting to speculate that the phosphorylation of PARP-1 by 
Erk is responsible for the decrease in PARP-1 activity. However, a report from Kauppinen 
et al. 18 appears to be in conflict with this hypothesis as the authors observed that the 
phosphorylation of PARP-1 by Erk1/2 is required for its full activation following treatment 
with the alkylating agent N-methyl-N’-nitro-N-nitrosoguanidine (MNNG). DNA-
independent PARP-1 activation can also be triggered by the direct interaction of PARP-1 
with phosphorylated Erk-2, an intriguing phenomenon in which PARP-1 is activated by a 
phosphorylated kinase without being phosphorylated itself 19. There is still some confusion 
in the literature with respect to the role of ERK on PARP activation. For example, a recent 
study from Ethier et al. 20 demonstrated that pADPr synthesis following MNNG-induced 
genotoxicity is unchanged in HeLa cells upon indirectly inhibiting ERK by treating cells 
with a specific inhibitor of its upstream regulator MEK. Another PARP-1 mediated 
mitogen-activated protein kinase pathway (MAPK) was implicated in the contribution of 
the c-Jun-N-terminal kinase 1 (JNK1) to PARP-1 activation in response to H2O2-induced 
cell death 21. In vitro phosphorylation assays have notably shown that PARP-1 is a direct 
phosphorylation target of JNK1.  
 
Other kinases such as the calmodulin kinase (CaMK) have been postulated to regulate 
PARP-1 activity. PARP-1 and calmodulin pathways were found to be targeted by sulphur 
mustard-induced apoptosis 22. The demonstration of PARP-1 activation by CaMK-II 
phosphorylation was reported by Ju et al. 23 in a model neurogenic gene activation pathway. 
Recently, membrane depolarization mediated by CaMK-II has been shown to induce 
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dissociation of the PARP-1 repressor KIF4 from PARP-1 through CaMK-II-dependent 
phosphorylation of PARP-1 which results in an activation of PARP-1 24.  
 
Recent observations have led to the view that PARP-1 signalling and involvement in DNA-
damage response could also be mediated by its phosphorylation. Indeed, dynamic changes 
in protein-protein interactions regulating the assembly of multiprotein complexes are 
mediated by the specific phosphorylation of some members of these complexes. For 
example, phosphorylation of PARP-1 is required for the association with Txk, a member of 
the tec family of tyrosine kinases 25.  
 
Casein kinase 2 (CKII) is involved in the phosphorylation and regulation of several DNA-
damage related proteins such as p53 26-28, BRCA1 29, XRCC1 30, 31 and RNA components of 
the translational apparatus 32, thus making this kinase a potentially interesting effector of 
PARP-1 mediated DNA-damage signalling pathway. One of the earliest reports suggesting 
that the cell's response to DNA damage is modulated by CKII-dependent protein 
phosphorylation is the work of Teitz et al. (1990) 33 in which authors reported that a 
Xeroderma pigmentosum cell line exhibits increased resistance to UV irradiation when 
transfected with a cDNA encoding a CKII subunit. Later, a defective CKII has been 
identified as a gene that affects cells' ability to adapt to the yeast’s DNA damage 
checkpoint 34. In addition, the DNA-binding functions of p53 following UV radiation-
induced DNA damage have been shown to be activated by phosphorylation of CKII sites 28, 
35, 36. The DNA damage response also involves the repression of genes whose products are 
components of the translational machinery 32. Indeed, CKII has been proposed as the 
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terminal effector in a signalling pathway that represses pol III transcription when genome 
integrity is compromised 37. The unanticipated role for CKII in the control of DNA-damage 
response (reviewed in 31) has been further supported by recent work from Loizou et al. 30 in 
which CKII phosphorylation of XRCC1 has been demonstrated to be required for assembly 
and activity of DNA single-strand break repair protein complexes. Moreover, the 
association of the novel DNA end processing factor APFL (aprataxin- and PNK-like factor) 
with XRCC1, which results in a recruitment of DNA single- and double-strand break repair 
machinery, requires CKII-specific phosphorylation 38, 39. A role for CKII in double-strand 
break re-joining is also proposed via the phosphorylation of histone H4 in nucleosomes 
proximal to the double-strand break. This phosphorylation is required for the maintenance 
of genome integrity and may reflect the modified histones functioning as binding sites for 
various DNA repair proteins 40. 
 
Finally, a link between PARP-1 and the cyclin-dependent kinase 5 (CDK5) has been 
proposed since silencing this kinase strongly sensitize cells deficient in homologous 
recombination to PARP inhibitors 41. Notably, CDK5 has been shown to be required for the 
DNA-damage response 41, 42. PARP-1 is also suspected to be a substrate of the integrin-
linked kinase (ILK) 43-45 and has been shown to be phosphorylated by the AMP-activated 
protein kinase (AMP-K) 46, resulting in a marked increase in PARP-1 activity. Thus, there 
is a compelling body of evidence converging towards a complex PARP-1 phosphorylation 
model involving multiple kinases with different consequences on PARP activity. 
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Collectively, these data indicate that phosphorylation is likely to play a significant role in 
the regulation of PARP-1 activity through both direct catalytic regulation and the regulation 
of the assembly of PARP-1 complexes. Because diverse signalling kinases may 
phosphorylate PARP-1, there is a potential for complex and dynamic regulation of PARP-1 
in response to changing biological conditions. To date, there are no reports indicating that 
PARG can be regulated by phosphorylation although endogenous phosphorylation sites 
were detected by large-scale mass spectrometry analysis of phosphoproteomes 47-50. 
 
This study has been undertaken to gain further insight into the phosphorylation status of 
PARP-1 and PARG with potential relevance to multiple biological functions. 
Phosphorylated PARP-1 and PARG were digested with trypsin and analyzed by mass 
spectrometry. Several phosphorylated amino acid residues were identified in both enzymes. 
The phosphorylation sites were further analyzed as potential phosphorylation sites using an 
in silico method employing neural network predictions for serine, threonine and tyrosine 
phosphorylation sites in eukaryotic proteins (NetPhos 2.0) 51 and predictions of kinase-
specific eukaryotic protein phosphorylation sites (NetPhosK 1.0 52 and Phoscan 53). Many 
PARP-1 phosphorylation sites are evolutionarily conserved and located within important 
functional domains, consistent with regulatory roles in vivo. Most intriguing is the 
clustering of PARG phosphorylation sites within the N-terminal putative regulatory 
domain. This suggests a confined and targeted phosphorylation pattern within the 
noncatalytic domain with potentially important regulatory effects on localization signals, 
caspase cleavage sites and putative protein-protein interaction motifs. 
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3. Materials and methods 
 
3.1 In silico prediction of PARP-1 and PARG phosphorylation sites 
 
FASTA formatted human PARP-1 and PARG amino acid sequences (Swiss-Prot accession 
numbers, PARP-1: P09874, PARG: Q86W56) were submitted to NetPhos 2.0 server 
(http://www.cbs.dtu.dk/services/NetPhos/) to generate neural network predictions for 
serine, threonine and tyrosine phosphorylation potential. A generic prediction score 
classification was applied to the dataset for the phosphoresidue prediction: low: 0 to 0.499, 
high 0.500 to 0.999. Kinase-specific protein phosphorylation site prediction employing ESS 
filtering (Evolutionary stable sites) on the NetPhosK 1.0 server 
(http://www.cbs.dtu.dk/services/NetPhosK/)  was also performed using the same sequence 
(threshold = 0.5). NetPhosK prediction of kinase-specific eukaryotic protein 
phosphorylation sites was performed with a dataset covering the following kinases: protein 
kinase A (PKA), protein kinase C (PKC), protein kinase G (PKG), casein Kinase II (CKII), 
cell division cycle 2 kinase (CDC2), calcium/calmodulin-dependent protein kinase type II 
(CaMK-II), serine-protein kinase Ataxia telangiectasia mutated (ATM), DNA-dependent 
protein kinase (DNA-PK), cyclin-dependent kinase 5 (CDK5), mitogen-activated protein 
kinase p38 (p38MAPK), glycogen synthase kinase 3 (GSK3), casein kinase I (CKI), protein 
kinase B (PKB), ribosomal S6 kinase (S6K), insulin receptor kinase (INSR), epidermal 
growth factor receptor (EGFR) and Src tyrosine kinase (SRC). These predictions were also 
corroborated by a Phoscan prediction of PARP-1 and PARG phosphorylation sites 
(http://bioinfo.au.tsinghua.edu.cn/phoscan/) using the following kinases with low 
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stringency lod-odds ratios: PKA, cyclin-dependent kinase (CDK), CKII, PKC, protein 
kinase B (PKB), mitogen-activated protein kinase (MAPK) and ATM. Predictions with 
consensus sequences were generated from the following kinase dataset: Myosin light chain 
kinase (MLCK), cGMP-dependent protein kinase (PKG), S6K, CaMK-I, CaMK-II, AMP-
activated protein kinase (AMP-K), extracellular signal-regulated kinase (ERK),  Polo-like 
kinase 1 (PLK1), RNA-dependent protein kinase (PKR), p21-activated kinase (PAK), 
Abelson tyrosine kinase (Abl), c-terminal Src protein kinase (CSK), epidermal growth 
factor receptor (EGFR), fibroblast growth factor receptor (FGFR), insulin receptor (IR), 
focal adhesion kinase (FAK), TGF-beta receptor (TGFR),  transforming growth factor beta 
receptor protein kinase (TGFbeta receptor PK), MAP kinase activated protein kinase 1 
(MAPKAP-1), MAPKAP-2, never in mitosis protein kinase (NIMA) and DNA-PK. 
 
3.2 Recombinant PARP-1 and PARG 
 
Purified human PARP-1 expressed in SF-9 insect cell line was obtained from Alexis 
Biochemicals (San Diego, USA). Recombinant PARG was expressed and purified 
essentially according to Invitrogen and Qiagen’s recommendations. E. coli BL21-AI™ 
(Invitrogen, Carlsbad, U.S.A.) transformed with OmicsLink™ (Genecopoeia Inc, 
Germantown, U.S.A.) vector (equivalent of Invitrogen’s pDEST17 (T7 promoter, N-His 
tag)) expressing full length 6X-His tagged human PARG protein was grown with shaking 
to an OD600 of 0.6 in a 37°C incubator, followed by the addition of 0.2% L-arabinose. Cells 
were harvested 120 min post induction by centrifugation and suspended in non-denaturing 
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lysis buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM imidazole and supplemented 
with Complete™ antiprotease (Roche Applied Science, Indianapolis, U.S.A.)) according to 
the manufacturer’s instructions. Cells were disrupted using five 10-second bursts at 200–
300 W with a 10-second cooling period between each burst. The lysate was then 
centrifuged at 10,000 x g for 10 min at 4°C to pellet cellular debris. The supernatant was 
applied to 5 ml Ni-NTA agarose beads (Qiagen) pre-washed with lysis buffer and mixed 
gently for 60 min at 4°C. The beads were washed three times with 30 ml of lysis buffer 
containing 20 mM imidazole. 6X-His tagged PARG was eluted from the beads using lysis 
buffer containing  250 mM imidazole.  
 
3.3 In vitro phosphorylation assays 
 
Kinases used for PARP-1 phosphorylation assays were obtained from Upstate 
Biotechnology (Charlottesville, USA) [Erk1, Erk2, CaMK-II, PKCα and PKCβ], New 
England Biolabs (Ipswich, USA) [CKII] and SignalChem (Richmond, BC, Canada) [JNK1 
and CDK5]. Phosphorylation reactions were carried out as recommended by the 
manufacturers in the presence of either cold or [γ-32P]ATP. One microgram of recombinant 
PARP-1 was used in each phosphorylation reaction. Plasmin was obtained from Sigma-
Aldrich Corp. (St. Louis, USA), and 2 μg of PARP-1 was digested with 35 ng of plasmin 
for 30 min at 30°C in phosphorylation buffer. Recombinant PARG (2 μg) was 
phosphorylated with 500 units of CKII (New England Biolabs, Ipswitch, U.S.A.) according 
to the supplier’s instructions. 32P-labeled PARP-1 and PARG were resolved by SDS-
 11
PAGE. After drying the gel, the radiolabeled proteins were visualized and quantified with 
an Instant Imager (Perkin-Elmer, Waltham, U.S.A), while unlabeled products were 
separated by SDS-PAGE and stained with Coomassie blue. 
 
3.4 Sample preparation of in vitro phosphorylated PARP-1 and PARG for MS analysis 
 
PARP-1 and PARG protein bands were manually excised from a SDS-PAGE gel and 
reduced with 10 mM dithiothreitol (Sigma-Aldrich, St-Louis, U.S.A.) for 30 minutes at 
37ºC and then alkylated with 55mM iodoacetamide (Sigma-Aldrich) for 30 minutes. In-gel 
protein digestion was performed overnight with 250 ng of mass spectrometry-grade trypsin 
(Promega, Madison, WI) at 37ºC. Peptides were extracted from the gel using a 50 % 
acetonitrile:water solution and dried out with a vacuum dryer (SpeedVac, Savant 
instrument, Holbrook, NY). 
 
3.5 LC-MS/MS Analysis 
 
Dried peptides were resuspended in 4 µl of 0.1% formic acid solution. On-line liquid 
chromatography of 2 µL of the resuspended sample was performed using a Thermo 
MicroAS autosampler and Surveyor MS pump (Thermo Electron, San Jose, U.S.A.). 
Chromatographic separation was achieved on a PicoFrit column BioBasic C18, 10 cm x 75 
µm (New Objective, Woburn, MA) with a linear gradient from 2% to 50% solvent B 
(acetonitrile, 0.1% formic acid) against solvent A (water, 0.1% formic acid) in 30 minutes, 
at 200 nL/min. The procedure for the analyses performed at the Taplin Facility (Harvard 
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Medical School, Boston, U.S.A.) was the following. A nano-scale reverse-phase HPLC 
capillary column was created by packing 5 µm C18 spherical silica beads into a fused silica 
capillary (75 µm inner diameter x 12 cm) with a flame-drawn tip. After equilibrating the 
column each sample was pressure-loaded off-line onto the column, and the column was 
then reattached to the HPLC system. A gradient was formed and peptides were eluted with 
increasing concentrations of solvent B (97.5% acetonitrile, 0.1% formic acid). 
 
Peptides eluted through the column directly into a LTQ linear ion trap mass spectrometer 
(Thermo Electron). Mass spectra were acquired using a data-dependent acquisition mode in 
which each full-scan mass spectrum (400 to 2000 m/z) was followed by collision-induced 
dissociation of the seven most-intense ions. The dynamic exclusion function was enabled, 
and the relative collisional fragmentation energy was set to 35%.  
 
3.6 Enrichment of phosphopeptides from endogenously phosphorylated PARP-1 
 
A dried peptide extract obtained from a tryptic digestion of 4 µg of recombinant PARP-1 
was enriched for phosphopeptides with TiO2 mono-tip from GL science (Tokyo, Japan). 
The TiO2 resin was preconditioned with 100% acetonitrile (ACN) and then conditioned 
with 0.2 M phosphate buffer pH 7.0. Peptides were reconstituted in 100 µl loading solution 
(350 mg/ml 2,5-dihydroxybenzoïc acid in 80% ACN and 0.1% trifluoroacetic acid (TFA)) 
and loaded on the tip. The TiO2 resin was washed with the loading solution followed by a 
second washing step with 80% ACN and 0.1% TFA. Phosphopeptides were eluted with 400 
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mM NH4OH and evaporated in a vacuum dryer (SpeedVac, Savant instrument, Holbrook, 
NY).  
 
3.7 MALDI MS analysis 
 
MALDI mass spectrometry was performed using both classical crystalline matrices and 
ionic liquid matrices (ILM). Classical 2,5-dihydroxybenzoic acid (DHB) (Sigma-Aldrich 
Corp) matrix was prepared in 50 % acetonitrile/water to final concentration of 150 mM 
while for ILM, 300 mM of DHB and 300 mM of n-Butylamine (BuA) (Fluka) were 
prepared in 50 % acetonitrile/water to final concentration of 150 mM. Analyses were 
performed using a MALDI quadrupole time-of-flight (QqTOF) mass spectrometer 
(QSTAR-XL, MDS Sciex / Applied Biosystems) equipped with an OMALDI 2 high-
repetition rate laser. Measurements were performed in both positive and negative ion mode. 
Data was collected using the Analyst QS 1.1 software and oMALDI server (MDS Sciex / 
Applied Biosystems). External mass calibration was achieved using standard peptides. 
Measurements using DHB were performed by searching for 5-10 hot spots, accumulating 
100 shots in total. All measurements were repeated in at least two independent experiments. 
 
3.8 Interpretation of MS/MS Spectra 
 
MS/MS spectra were first processed with Sequest using a two-pass approach, similar in 
design and implementation to the second, “refinement” pass of TheGPM’s search engine  
(http://www.thegpm.org) 54. The first pass was used to identify which proteins were present 
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in the sample whereas the second pass maximized the number of correctly identified 
phosphopeptides. For both passes, tandem mass spectra were extracted from the LTQ raw 
files by BioWorks version 3.2 and analyzed using Sequest (Thermo Scientific, San Jose, 
CA; version 27 rev. 12), with a fragment ion mass tolerance of 1.0 Da and a parent ion 
tolerance of 2.0 Da. The first pass reasonably assumed the existence of two detectable and 
minimally modified tryptic peptides for each protein present in the LC-MS/MS sample. For 
the first pass, Sequest was set up to search the International Protein Index’s human database 
(version 3.30) 55 supplemented with a few common contaminants. The only fixed and 
variable modifications specified were respectively cysteine carbamidomethylation and 
methionine oxidation. Scaffold (version Scaffold_2_01_01, Proteome Software Inc., 
Portland, OR) was used to validate MS/MS-based peptide and protein identifications. 
Peptide identifications required deltaCn scores greater than 0.10 and XCorr scores greater 
than 1.8, 2.5, and 3.5 for singly, doubly, and triply charged peptides respectively. Protein 
identifications were accepted if they contained at least 2 identified peptides. For the second 
pass, each biological sample was processed separately. This time, Sequest was set up to 
search a sample-specific protein sequence database containing only those proteins 
identified in the sample during the first pass. Tryptic digestion with a maximum of 3 
internal missed cleavages was assumed. Cysteine carbamidomethylation was specified as a 
fixed modification whereas oxidation of methionine and phosphorylation of serine, 
threonine and tyrosine were specified as variable modifications.  
 
Scaffold (Proteome Software) was used to filter out second-pass peptide spectral matches 
(PSMs) with XCorr scores lower than 2.0 and annotate the fragments of the remaining 
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MS/MS spectra. Every PSM corresponding to a possible PARP-1 or PARG phosphopeptide 
was manually validated for a high-quality match and, in the case of 
phosphoserine/threonine-containing peptides, for a strong MS/MS fragment corresponding 
to the neutral loss of phosphate from the precursor. Finally, when many possible 
phosphorylation sites existed within the identified phosphopeptide, the Ascore from 
Beausoleil et al. (2006) 49 was computed using the authors’ server 
(http://ascore.med.harvard.edu) in order to determine whether or not the phosphorylation 
could be confidently assigned to a specific residue. The Ascore is a probability-based score 
which measures the probability of correct phosphorylation site localization based on the 
presence and intensity of site-determining ions in the phosphopeptide MS/MS spectrum. 
 
3.9 Plasmid constructs and mutagenesis 
 
Plasmids used for GFP-tagged PARP-1 expression were all based on the constructs 
described previously 56, 57. Point mutations were introduced by site-directed mutagenesis 
(QuikChange mutagenesis kit (Stratagene)). Successive mutagenesis rounds were used to 
produce S27-S32-S41 triple mutants. The sequences of primers used for the various 
mutants are: S27D [5-CGTTCTTTACGTCGCTCCTGTAGGGGTTCCTGAGC-3], S32E 
[5-CGTAGGGGTTCCTGCTCGAGGCCTACCGGTAGTACC-3] and S41E [5-
CCTACCGGTAATACCACGTCCTCGGGTACAAACTACC-3]. In order to prevent 
hairpin loops, a silencing mutation was introduced at the codon corresponding to I37. 
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3.10 Two-photon micro irradiation 
 
The evaluation of recruitment kinetics of PARP-1 phosphomutants was performed 
essentially as described 56 with the exception of the following modifications. After 
overnight transfections with Effectene reagent (Qiagen), HeLa cells were placed in medium 
containing 1 µg/ml Hoechst 33258 for 30 minutes. The medium was then removed and 
replaced with fresh one. A 37oC pre-heated stage was used for the acquisition period on the 
Zeiss LSM510 NLO laser-scanning confocal microscope. Because of the rapid 
accumulation but longer duration of accumulation of PARP-1 at sites of DNA damage, 
multiple acquistion rates were used. For the 30 first seconds, 20 images were collected 
every 250 ms followed by 10 images for 500 ms and 10 images for 2 s. The following 20 
pictures were collected for 36 s for a total of 60 images over 12.5 min. Background and 
photobleaching corrections were applied to each datasets as described 56. 
 
4. Results and discussion 
 
4.1 In silico prediction of PARP-1 generic phosphorylation sites 
 
Prediction of phosphorylation sites were generated using NetPhos 51 and Phoscan 53 servers, 
which are both integrated systems for accurately predicting the location of phosphorylation 
sites. The first approach lies in the estimation of the phosphorylation potential of PARP-1 
and PARG using S/T/Y "sequence logos" that represent the sequence context at 
experimentally verified phosphorylation sites. The NetPhos algorithm calculates a 
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probability score for a phosphorylation at a given position. This computational prediction 
approach generates a generic score which is correlated to the likelihood of a 
phosphorylation without specificity determinants for a single kinase. This prediction 
approach is a valuable tool to pinpoint protein areas where phosphorylation has a high 
potential to occur and can assist in the determination of functionally important regulatory 
domains within a protein. Using this strategy, PARP-1 and PARG were subjected to 
sequence-based phosphorylation site prediction. The phosphorylation potential is depicted 
by a color-coded S/T/Y bar graph with respect to each protein amino acid sequence (Figure 
1A and 1B, see Supplementary Table S1 for detailed prediction scores and complete PARP-
1 and PARG Serine/Threonine/Tyrosine (S/T/Y) coverage). Putative highly 
phosphorylatable PARP-1 residues are dispersed throughout the amino acid sequence but 
specific regions appear more likely to be phosphorylated (Fig. 1A). Notably, the first N-
terminal zinc finger domains and the region centered around the BRCT domain have higher 
phosphorylation potentials. In contrast, the phosphorylation potential is remarkably low in 
the PARP signature motif that comprises the active site. The consequences of 
phosphorylated residues in functional and regulatory domains of PARP-1 are poorly 
understood but the identification of potential phosphorylation sites in specific areas can 
help in the design of targeted mutagenesis experiments. The increased susceptibility of 
phosphorylation of important motifs can also be taken into account when designing 
functional studies. 
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4.2 In silico prediction of PARG generic phosphorylation sites 
 
In contrast to PARP-1, which displays a dispersed putative phosphorylation pattern 
throughout most of its amino acid sequence, PARG most probable phosphorylation sites are 
clustered in the N-terminal part of the protein comprised of the first four exons (Fig 1B). 
This clustering of predicted phosphorylation sites is even more dramatic in the region 
surrounding the two caspase-3 cleavage sites. A closer analysis of this particular region 
reveals that the amino acid composition makes it an acidic region, which contrasts with the 
basic charge of the catalytic domain 58. This acidic region is highly enriched in consensus 
CKII phosphorylation sites (Supplementary Table S1). Interestingly, a characteristic pattern 
of CKII phosphorylation in acidic regions has been reported for several proteins 59-63, 
making CKII a prototypic acidic-directed kinase. 
 
The preferential localization of putative phosphorylation sites within PARG N-terminal 
region suggests that this posttranslational modification might be important in the regulation 
of PARG activity. However, the N-terminal part of PARG, to which has been assigned a 45 
kDa putative regulatory domain, remains to be characterized with respect to the regulation 
of PARG catalytic activity. Nonetheless, subcellular localization and susceptibility to 
caspase cleavage are a consequence of specific signals located within this N-terminal 
region. 
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4.3 Prediction of specific kinase phosphorylation sites in PARP-1 and PARG  
 
NetPhosK and Phoscan were also used to predict PARP-1 and PARG kinase-specific 
phosphorylation sites from PARP-1 and PARG (Suplementary Table S2) as these 
predictions help interpret mass spectrometric results, namely why some sites appear to be 
phosphorylated only by a specific kinase. NetPhosK and Phoscan use different methods to 
generate kinase-specific predictions. NetPhosK is based on a machine learning technique 
called "artificial neural networks" that computes a probability score accounting for the 
sequence variations around the kinases acceptor sites. NetPhosK also examines 
homologous phosphorylation sites in related species to improve prediction reliability 
(evolutionary stable sites filtering). For each putative S/T/Y phosphoresidues, NetPhosK 
estimates which kinase is more likely to find its substrate given the kinase’s general 
phosphorylation pattern. Kinase-specific phosphorylation modelling has been further 
developed by Li et al. 53 with the Phoscan program. Phoscan integrates biological 
information regarding amino acid composition in the neighbourhood of phosphorylation 
sites and kinase-specific features for recognizing substrates. Phoscan integrates 
phosphorylation potential predictions of candidate sites based on their amino acid 
composition to kinase-specific features for recognizing substrates as reported in the 
literature, resulting in a more accurate prediction.  
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4.4 Mass spectrometry analysis of PARP-1 and PARG phosphoresidues 
 
We were inspired to map PARP-1 and PARG kinase-specific phosphorylation sites by mass 
spectrometry for two reasons. First, although in silico prediction of phosphorylated residues 
within PARP-1 and PARG sequences is a remarkable tool to designate residue candidates 
for functional analysis, experimental validation of a given phosphorylation site increases 
the probability that it could be functionally relevant. Secondly, while some kinases are 
known to phosphorylate PARP-1, there is currently very little information in the literature 
in relation to the exact phosphorylation sites. Kinase-specific mapping was accomplished 
by subjecting recombinant PARP-1 to phosphorylation by kinases suspected to be involved 
in PARP-1-dependent pathways such as PKC, Erk-1/2, CaMK-II, JNK1 and CDK5. CKII 
phosphorylation sites were investigated in both PARP-1 and PARG since there is 
accumulating evidence of CKII as a key participant in the cellular response to DNA 
damage 31. Moreover, the identification of CKII phosphorylation sites in PARG is 
particularly interesting seeing that predicted CKII phosphorylation sites are abundant in the 
N-terminal PARG regulatory region (Supplementary Table S1). 
 
4.4.1 PARP-1 phosphomapping 
 
Considering the initial reports of phosphorylation of PARP-1 by PKC 12, 13, 64 and the 
overrepresentation of predicted PCK phosphorylation sites in PARP-1 (about one third of 
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all predicted sites (Supplementary Table S1)), we first incubated human PARP-1 with PKC 
α and β in the presence of [γ-32P]ATP. In both cases, we observed strong phosphorylation 
of PARP-1 (Fig. 2A). Since the signal was stronger with PKCβ, we used this kinase to 
phosphorylate PARP-1 with unlabeled ATP and perform LC-MS/MS on the trypsin-
digested, phosphorylated PARP-1. Three phosphopeptides were identified, two containing a 
phosphoserine (S504 and S519) and one containing a phosphothreonine (T656). Table 1 lists all 
the phosphopeptides and the phosphorylated residues identified by mass spectrometry. 
SEQUEST Xcorr and deltaCn scores, which are indicative of the quality of the peptide-
spectral match are presented for each phosphopeptide identified by MS/MS. 
 
Post-translational modifications such as phosphorylation can be observed by mass 
spectrometry since they shift, by a characteristic value, the mass of the modified peptide 
and of all its collision-induced fragments bearing the modification. For instance, 
phosphorylation increases the mass of the peptide and of the MS/MS fragments bearing the 
phosphate by 79.97 Da. Furthermore, in the case of phosphoserine/threonine-containing 
peptides, collision-activated dissociation generates, additionally to the usual b- and y- 
peptide fragments, a very intense fragment corresponding to the neutral loss of phosphoric 
acid (H3PO4, 97.98 Da) from the phosphorylated peptide. This approximately 98 Da neutral 
loss is characteristic of phosphoserine or phosphothreonine (but not phosphotyrosine) and 
its observation confirms that a phosphopeptide has been fragmented. At times, it is 
observed not only for the precursor (fragmented peptide) but also for some of the 
phosphorylated b- and y-ions. The phosphopeptides reported in Table 1 all bear phosphate 
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groups on either serine or threonine residues (never tyrosine). Consequently and as 
expected, an  approiximately 98 Da neutral loss from the precursor was observed on the 
MS/MS spectrum for each of them (see Figure 3 for a representative phosphopeptide 
MS/MS spectrum), validating the presence of a phosphorylated peptide. A comprehensive 
list of all phosphopeptides observed for each kinase is presented in Supplementary 
Information, along with the phosphopeptides’ annotated MS/MS spectra and MS/MS 
fragmentation tables. 
 
To add confidence to the localization of those PKCβ sites, we digested phosphorylated 
PARP-1 with plasmin, which cleaves the protein in three polypeptides of   29 kDa, 36 kDa 
(both N-terminal) and 56 kDa (C-terminal) 65. As expected, only the 56 kDa carboxy-
terminal fragment was observed to be phosphorylated (data not shown), confirming the 
absence of a phosphorylation site in the amino-terminal portion of the enzyme. Similar 
results have been obtained by Bauer and collaborators 13. 
 
The application of MS/MS analysis to in vitro-phosphorylated PARP-1 by PKCβ resulted 
in the identification of three phosphoresidues in the vicinity of the protein’s C-terminus that 
were predicted to be PKC phosphorylation sites. All these locations meet a general PKC 
consensus phosphorylation sequence although serines S504 and S519 , which are both 
localized in the automodification domain, are predicted to be in a more phosphorylatable 
environment than the threonine T656. This information, coupled with the fact that S504 and 
S519 are evolutionarily conserved among mammalian PARP-1, as opposed to T656, makes 
them good candidates for the study of PKC-dependent PARP-1 regulation. 
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In vitro phosphorylation of PARP-1 by Erk-1, Erk-2, CKII, CDK5, JNK1 and CamK-II  
was also examined relative to PKCβ. Fig. 2B shows that all these kinases phosphorylate 
PARP-1, albeit at lower levels than PKCβ. Ten phosphopeptides were identified by LC-
MS/MS in PARP-1 samples incubated with Erk-1 (Table-1). Kauppinen and collaborators 
have reported the phosphorylation of PARP-1 by Erk-1 18 but were not able to identify the 
phosphorylation sites using mass spectrometry. Additional mass spectrometry analysis of 
Erk-2 phosphorylation products led to the detection of a doubly-phosphorylated 
phosphopeptide (368-TPPPSTASAPAAVNSSAS-385, Kauppinen T., personnal 
communication) bearing three potential phosphorylation sites: T368, S372, and T373. Mutation 
studies revealed that phosphorylation of S372 and T373 activates PARP-1 activity while 
phosphorylation of T368 has no effect on PARP-1 activity. We also identified a singly 
phosphorylated Erk-1 phosphopeptide phosphorylated at either T368, S372, T373, or S374 
(Table 1). Precise localization of phosphorylated residues in peptides containing multiple 
S/T/Y is particularly challenging. To assist us in the interpretation of MS data, we used a 
probability-based approach that measures the probability of correct phosphorylation site 
assignment based on the presence and intensity of site-determining ions in the MS/MS 
spectrum 49. This approach generates a score, called the Ascore, for each S/T/Y amino acid 
residues found in the phosphopeptide. It has been shown that greater than 99.8% of 
peptides with Ascore ≥ 19 were localized correctly in the large datasets used to validate the 
statistical approach 49. For several of the phosphopeptides observed in this study, the 
Ascore values indicated that the phosphorylation sites could be confidently assigned but 
others still lack site-determining MS/MS ions such as the Erk-1 phosphopeptide 
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IFPPETSASVAATPPPSTASAPAAVNSSASADKPLSNMK bearing an equivocal 
phosphorylation site (either T368, S372, T373, or S374; Table 1). In silico, kinase-specific 
phosphorylation site prediction can make a contribution to the interpretation of 
phosphopeptide spectra and help determine which sites should be given further 
experimental consideration. 
 
Two independent LC-MS/MS investigations to discover CKII phosphosites failed even 
though CKII does phosphorylate PARP-1 in vitro (Fig. 2B). This is likely due to the low 
level of phosphorylation obtained after incubation with CKII, and/or to intrinsic 
characteristics of the CKII-phosphorylated tryptic peptides which prevented their mass 
spectrometric detection  (too large a mass, too many positive charges, low ionizability, low 
solubility, etc.).  
 
Recently, Ju and collaborators 23 proposed a model of neurogenic gene activation in which 
phosphorylation of PARP-1 by CaMK-II is a central event. We therefore tested whether 
this kinase could phosphorylate PARP-1 in vitro. Fig. 2B shows that CaMK-II can 
phosphorylate PARP-1 although at a much lower level than the other kinases tested. Even 
though PARP-1 is barely phosphorylated by CaMK-II, two phosphopeptides were 
identified for this kinase (Table 1), revealing potential CaMK-II phosphorylation sites 
ambiguously positioned respectively at S257/T258 and S782/S785. S257 and S782 are, however, 
the only sites predicted by Phoscan to be within a CaMK-II phosphorylation motif (Table 
2). 
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Identification of phophorylation sites from PARP-1 phosphorylated in vitro by JNK1 and 
CDK5 led to the identification of the same phosphoresidues as those obtained with CaMK-
II (Table 1). As seen on figure 2B, the level of phosphorylation achieved by Erk-2, CKII, 
CDK5, JNK1 and CaMK-II is significantly lower than that of PKCβ and Erk-1 for which 
we identified several unique phosphorylation sites. This suggests that, for Erk-2, CKII, 
CDK5, JNK1 and CaMK-II, the low stochiometry of phosphorylated PARP-1 relative to 
the unphosphorylated state prevents optimal mass spectrometric analysis. Indeed, the 
analysis of phosphorylated peptides by mass spectrometry has always been challenging 
because of their intrinsically low abundance and poor ionization.  
 
The recombinant PARP-1 used in the present study has been produced in SF-9 insect cells. 
We were aware that endogenously in vivo phosphorylated sites could be present prior to 
phosphorylation assays. To better understand these in vivo phosphorylated sites and to 
distinguish them from kinase-specific phosphorylation sites, we also performed for PARP-1 
a general mass spectrometric screening of endogenously phosphorylated residues. 
However, because of the low stoichiometry and therefore low abundance of endogenously 
phosphorylated PARP-1, a phosphopeptide enrichment step was required in order to 
increase our chance of acquiring phosphopeptide spectra. Several approaches have been 
developed to enrich phosphoproteins and phosphopeptides for MS analysis 66 such as anti-
phosphoresidue  immunoprecipitation, affinity chromatography and chemical modification. 
Immobilized metal affinity chromatography (IMAC) and titanium dioxide (TiO2) 
chromatography are two common methods performed to selectively enrich 
phosphopeptides based on the chemical affinity of these resins to the phosphate group. 
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IMAC and TiO2 are complementary since they tend to exhibit differential affinities towards 
mono- or multiphosphorylated peptides. Recent optimization of the TiO2 procedure makes 
it more appropriate for some applications and specifically for matrix-assisted laser 
desorption ionisation (MALDI) mass spectrometry 67. We chose to enrich the tryptic digest 
using TiO2 because we wanted to analyze the enriched tryptic extract using both 
Electrospray ionization (ESI) and MALDI as these two ionisation modes are known to lead 
to the detection of complementary sets of peptides and thus increase protein sequence 
coverage 68. Three PARP-1 phosphopeptides were identified from MALDI MS analysis of 
TiO2 enriched peptide extracts (Table 1). Unfortunately, these phosphopeptides were 
identified solely through their measured mass-to-charge ratio as ion signal intensity was 
weak and MS/MS signal did not rise above noise level. On the other hand, LC-MS/MS with 
the LTQ led to the MS/MS confirmation of one the phosphopeptide observed by MALDI, 
as well as the MS/MS identification of three phosphopeptides not seen by MALDI (Table 
1). All in all, six phosphopeptides were detected, confirming the endogenous 
phosphorylation of PARP-1 produced in insect cells.  
 
Dephosphorylation of recombinant human PARP-1 with calf intestinal alkaline phosphatase 
(CIAP) has been shown to drastically reduce its enzymatic activity 18, suggesting that 
phosphorylated residues are essential to PARP-1 catalytic activity. Table 2 summarizes the 
information stored in Table 1 by displaying it in a simplified array format. This enables a 
global view of PARP-1 endogenous and kinase-specific phosphorylation sites along with 
corresponding in silico phosphorylation predictions:  all the phosphorylation sites identified 
by mass spectrometry are listed relative to their experimental context and the consensus 
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kinase recognition sites predicted by in silico computations. In addition, phosphorylation 
sites reported in the literature are also shown so as to complete the list of currently-known 
phosphorylation sites for both PARP-1 and PARG. Of particular interest is S782, a 
phosphosite found by MALDI TOF MS of endogenously phosphorylated PARP-1 and 
confirmed by LC MS/MS. This site has been consistently identified with high confidence 
for Erk1, CamK-II, JNK1 and CDK5, which is not unexpected since it was present prior to 
the phosphorylation assay. Its identification is recurrent in most of the analyzed samples 
and it is thus likely to be an authentic endogenously phosphorylated residue. In a similar 
way, the phosphorylation site S257/T258 (S257 or T258 ) found within two phosphopeptides 
from endogenous PARP-1 was also found in Erk-1, CaMK-II and JNK1. The repeated 
identification of the same phosphorylated residues from independent phosphorylation 
assays strongly supports its validation as an actual phosphorylation site. 
 
Knowing which sites are phosphorylated endogenously in PARP-1 is not only important for 
the understanding of PARP-1 regulation under physiological conditions but also to add 
confidence in the identification of S/T/Y residues phosphorylated by specific kinases. 
Considering the phosphorylation sites present in recombinant PARP-1 prior to the in vitro 
assays, we can isolate T335 as a unique endogenous phosphosite not detected in any of the in 
vitro kinase-specific phosphorylated extracts. Likewise, S41, S177, T420/422, S455 and S542 are 
specific to Erk-1 while S504 and S519 are specific to PKCβ. Alternatively, we could have 
dephosphorylated recombinant PARP-1 with a phosphatase prior to the in vitro kinases 
assays in order to overcome the ambiguity in the assignement of a phosphosite to a specific 
kinase. However, it can be challenging to work with phosphatases when looking for low-
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abundance phosphorylation sites. Moreover, these endogenous phosphorylation sites seem 
to guide the phosphorylatability of PARP-1 with respect to some kinases as 
dephosphorylated PARP-1 does not achieve the same level of phosphorylation than 
untreated PARP-1 and significant impacts PARP-1 activity (Gagné J.-P. et al., unpublished 
data). 
 
4.4.2 PARG  phosphomapping 
 
At the time this study was undertaken, the only posttranslational modification known for 
PARG was an endogenous phosphorylation at S316, which is located next to a caspase 
cleavage site, identified in a large-scale phosphorylation analysis of HeLa nuclear proteins 
47. This position is predicted to be an evolutionarily conserved CKII consensus 
phosphorylation site 10. In recent years, several lines of evidence have indicated that CKII is 
involved in the regulation of apoptosis, cell cycle and the DNA-damage response 69-72 
(reviewed in 73), three biological processes in which pADPr has been clearly shown to have 
regulatory functions 74. The over-representation of putative CKII phosphorylation sites in 
the N-terminal regulatory domain of PARG, especially in the acidic region that bears the 
two caspase cleavage sites, also inspired us to determine whether or not CKII could 
actually phosphorylate PARG. Using affinity-purified PARG over-expressed in E.coli , we 
found that PARG is indeed a good substrate for CKII (Figure 2C) and validated by mass 
spectrometry S316 as a CKII phosphorylation site (Table 1).  
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We also identified 7 other phosphorylation sites and, out of these, 6 are located in the N-
terminal putative regulatory region (Table 1). Furthermore,  a study from Villen et al. 48 
identified additional phosphorylation sites (S137, S261, S264) in the N-terminal region of 
PARG (Table 2). Therefore, besides S962/966 located close to the C-terminus, all identified 
phosphorylation sites were found in the putative regulatory domain of PARG, raising the 
possibility that phosphorylation events might modulate PARG functions. For instance, one 
could hypothesize that the addition of the negative charges from the phosphate groups 
could impair binding of negatively charged pADPr to PARG and thus modify the affinity of 
PARG to its substrate. Phosphorylation of PARG could also result in unexpected 
conformational changes with consequences on activity and protein-protein interactions, or 
caspase cleavage protection as this has been reported for the caspase substrates Bid 72, Max 
75  and PTEN 71. Further work is in progress to test these hypotheses. 
 
In view of the scarcity of information regarding PARG regulation mechanisms and the lack 
of known effectors that could be involved in its control, the phosphomapping of PARG 
phosphorylation sites coupled with mutagenesis studies to determine whether 
phosphorylation sites are linked to changes in PARG behaviour may significantly improve 
our understanding of PARG regulation. 
 
4.5 Coupling in silico prediction of phosphorylation sites to phosphopeptide analysis 
 
As it can be seen from Table 2, several phosphopeptides bear ambiguity on the exact 
phosphorylation site; however computational prediction algorithms such as NetPhosK and 
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Phoscan can help determine the exact phosphorylation sites. The determination of a highly-
probable phosphorylation site assigned to a specific kinase is particularly valuable for the 
design of mutagenesis experiments. The phosphorylation potentials shown in Figure 1A 
and 1B corresponding to phosphorylation sites within conserved domains of PARP-1 and 
PARG may also be used to target the most relevant positions related to functional 
regulation by specific kinases. For example, one could prioritize S257 over T258 to be 
mutagenized in a functional assay since, in the PARP-1 phosphopeptide 
KVCpSpTNDLKELLIFNK from which these sites originate, S257 is predicted to be in an 
environment highly favorable to phosphorylation compared to T258. Predicted kinase-
specific phosphorylation sites in phosphopeptides bearing ambiguous phosphosites should 
also be favoured when planning mutagenesis strategy for functional analysis.  
 
Coupling computational approaches to MS analysis contributes to more targeted 
mutagenesis experiments which could result in significantly reduced validation procedures. 
The consolidation of this information with characterized protein domains, motifs or 
evolutionarily conserved regions will further help us in unravelling the functionality of 
posttranslational modifications.  
 
4.6 Structure-function modeling of phosphorylated residues of PARP-1 in functional 
domains 
 
 
The localization of phosphorylated residues in PARP-1 revealed by mass spectrometry can 
be coupled to conformational analysis of the crystallographic data. In contrast to PARG, for 
which there is no three-dimensional structure available, most of the PARP-1 structure has 
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been determined. Thus, localization of the phosphorylated residues in three-dimensional 
models was investigated. Figure 4 shows the localization of phosphoresidues in functional 
motifs of PARP-1. Phosphorylation sites can be pinpointed in the three zinc-finger motifs 
(Figure 4a, 4b, 4c), the BRCT domain (Figure 4d), WGR motif (Figure 4e) and the C-
terminal catalytic fragment of PARP-1 (Figure 4f). The first N-terminal zinc-finger of 
PARP-1 is structurally very similar to a homologus domain in DNA ligase III (Figure 4a).   
A study of the DNA ligase III DNA-binding surface reported by Kulczyk et al.76 revealed 
that amino acids residues located in the extended loop of the finger are strongly affected by 
the addition of DNA, confirming the importance of the finger loop for DNA-binding, an 
observation that is very likely to apply to the PARP-1 first zinc-finger. Interestingly, both 
DNA ligase III and PARP-1 present a highly conserved serine residue in the extended loop 
required for DNA-binding. This serine residue, S41, has been found in PARP-1 extracts 
from in vitro phosphorylation assays by Erk-1. Phosphosite S32 was also identified as an 
endogenous PARP-1 phosphorylation site from MALDI MS analysis (Table-1). This 
suggest that the DNA-binding of PARP-1 could be regulated by phosphorylating specific 
residues within the zinc fingers. Following the same idea, figure 4b shows two 
phosphorylation sites in the second zinc-finger of PARP-1 (S177 and S179). These sites are 
located in a highly flexible part of the zinc-finger structure connecting the two helices. In 
contrast to the first zinc-finger of PARP-1, these phosphorylation sites are not located in the 
extended loop or the β-sheets that make contact with DNA so the impact on DNA-binding 
would probably less dramatic as it was  proposed for DNA ligase III. 
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Figure 4c represents the third zinc-finger of PARP-1 in a dimer model developed by 
Langelier et al.77. Indeed, apart from being a zinc-binding structure that also mediates 
interdomain communication, the authors reported that this motif self-associates in the 
crystal lattice, forming an extensive homodimer interface. Endogenous phosphorylations 
sites (S257/T258 and T335) were localized near the dimer interface (Figure 4c) thus inviting to 
the speculation that phosphorylation of this position might affect the protein dimerization 
interface. 
 
Phosphosites unique to Erk-1 were localized in the BRCT domain of PARP-1 (Figure 4d), 
an important protein-protein interaction motif found predominantly in proteins involved in 
cell cycle checkpoint functions responsive to DNA damage (e.g. XRCC1, DNA ligase III, 
BRCA1, 53BP1, MDC1). The functional consequences of phosphorylating the BRCT 
domain of PARP-1 are unknown. However, the kinase Aurora-B has been reported to bind 
PARP-1 via the BRCT motif and to phosphorylate PARP-1 78. The BRCT domain of 
PARP-1 is highly similar to the BRCT domain of XRCC1 (Figure 4d). The core of the 
BRCT domain is composed of β-sheets important for adequate folding of the structure. 
Indeed, mutations in the core of XRCC1 BRCT motif (V584 and I585) has been shown to 
disrupt the interaction between XRCC1 and DNA ligase III 79. T420 and S455 phosphosites 
are also localized in the β-sheets of PARP-1 BRCT domain. It would be interesting to know 
how a phosphorylated BRCT domain  of PARP-1 will behave in a context of protein-
protein interactions with its partners.  
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Finally, three phosphosites are found in the PARP regulatory domain within the C-terminal 
catalytic domain of PARP-1 (Y775, S782, S785 or S786) that could also be involved in the 
regulation of PARP-1 activity. These sites are localized in a flexible and highly accessible 
loop of the catalytic domain (Figure 4f). Previous studies have shown that phosphorylation 
sites are mainly located in parts of proteins without regular structure such as hinges and 
loops 80-83. A closer look at the N-terminal domain of PARG reveals that this region is 
predicted to be an extended loop region. Indeed, a secondary structure prediction of PARG 
on the PredictProtein server 84 indicates that a NORS 85 (NOn-Regular Secondary 
Structure) spans the entire putative regulatory domain of PARG where most of the 
phosphorylation sites are clustered. 
 
Following the same idea, unstructured interdomain regions of PARP-1 are thought to 
present structural attributes favorable to phosphorylation. This seems to be applicable to 
this study since several phosphorylation sites are localized within inter domain regions of 
PARP-1 (Figure 1a) for which no structural data is available. However, these 
phsophorylation sites located ouside characterized motif have proven to be of great 
importance in the regulation of PARP-1 activity. Indeed, the phosphosites S372 and T373 
located between the third zinc finger and the BRCT domain of PARP-1 (Figure 1a) are Erk 
phosphorylation sites reported by Kaupinnen et al. to be required for full activation of 
PARP-1 18. We also identified these sites in an endogenously phosphorylated peptide 
bearing multiple phosphorylatable residues (IFPPETSASVAApTPPPpSpTApS-
APAAVNSSASADKPLSNMK, see Table-1). A cluster of phsophorylated serine residues 
is also present between the BRCT and the WGR domain of PARP-1 (S509, S519, S542, Figure 
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1a) and a single phosphothreonine residue (T656) is located between the WGR and the PRD 
domains. The analysis of the 3D coordinates of the WGR motif of PARP-1 that extend 
outside the motif in the N-terminal direction shows that phosphoresidues S519 and S542 are 
actually in unstructured and flexible regions (Figure 4e). Inspection of the tertiary structure 
of PARP-1 coupled to localization of the phosphorylations sites revealed by mass 
spectrometry analysis is particularly interesting in a structure-function evaluation and to 
target phsophosites for further experimental validation.  
 
4.7 In vivo validation of some  PARP-1 phosphosites in a context of DNA damage 
signaling 
 
The recruitment of PARP-1 at sites of DNA damage and its subsequent activation result in 
a rapid and transient accumulation of pADPr. Recent studies suggest a mechanism by 
which pADPr-binding interaction may contribute to the initial damage signalling that leads 
to the recruitment of DNA repair proteins 56, 86, 87. Because altering the properties of PARP-
1 recruitment during the initial DNA-damage response is likely to have a large impact on 
the damage signalling and the subsequent DNA repair process, we analyzed the recruitment 
kinetics of selected phosphorylation sites in this context. 
 
The analysis of site-specific PARP-1 phosphorylation in response to direct phosphorylation 
by Erk1 and Erk2, reported by Kauppinen et al. 18, is the only study that provides a link 
between PARP-1 phosphorylation at specific sites and enzymatic functions. In our study, 
we report several new Erk1 phosphorylation sites (Table 1). Of particular interest is the 
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Erk-1 phosphosite found at S41, a typical (S/T)P proline-directed MAPK phosphorylation 
consensus found in a variety of substrates of MAP-related kinases. The phosphosite S41 is 
similar to the S372 phosphosite validated by Kauppinen and colleagues, which was another 
consensus proline-directed MAPK phosphorylation site. Moreover, the evolutionarily 
conserved S41 is predicted by both kinase-specific computational tools as a MAPK 
phosphorylation site (Table 1). Therefore, S41 and other proximal phosphorylation sites (S27 
and S32) were selected as good candidates for in vivo validation. 
 
Using laser microirradiation-induced DNA damage, we analyzed the recruitment kinetics of 
GFP-PARP-1 phosphomutants within the first N-terminal zinc finger domain of PARP-1. 
Single and triple glutamate- and aspartate-substituted derivatives designated S27D-S32E-
S41E were generated to mimic a permanently phosphorylated protein. Figure 5 shows that a 
single mutation at S41 severely impairs the recruitment and persistence of PARP-1 at DNA 
damage sites while similar substitutions at phosphosites S27 and S32 show little divergence 
compared to the wild-type protein. A triple substitution including proximal serine 
phosphorylation sites (S27D-S32E-S41E) do not show additive effects indicating that the 
altered kinetics observed for the triple phosphomutant are a consequence of the single 
contribution of site S41. This observation suggests that the phosphorylation of PARP-1 may 
be part of a regulation mechanism to delocalize the enzyme from the DNA damage site and 
limit the extent of poly(ADP-ribosylation) and NAD depletion in the nucleus. This is the 
first demonstration of phosphorylation-dependent dynamics of PARP-1 using live cell 
imaging combined with laser microirradiation. 
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5. Concluding remarks 
 
Cataloguing PARP-1 and PARG protein phosphorylation states represents a major 
challenge given that this posttranslational modification occurs at low stoichiometry, 
includes dynamic and reversible states with spatiotemporal regulation within cells. Even 
though global phosphoproteome analysis has provided valuable information and has led to 
the discovery of new phosphorylation sites, these are primarily abundant sites. Indeed, 
almost all phosphopeptides found with large-scale analysis or with endogenously-modified 
recombinant proteins correspond to high-potential phosphorylation sites. More targeted 
strategies, such as that used in the present study, which include specific coverage of kinases 
and phosphopeptide enrichment techniques will deepen of understanding of how the 
various phosphorylated isoforms of PARP-1 and PARG regulate the functions and 
activities of these enzymes  
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Figure legends 
 
Fig. 1. Diagrammatic representation of PARP-1 (A) and PARG (B) phosphorylation sites. 
An in silico-based prediction approach was used for the analysis of phosphorylation sites 
within the primary amino acid sequences of PARP-1 and PARG. The phosphorylation sites 
were predicted by the NetPhos program which evaluates serine, threonine and tyrosine 
(S/T/Y) phosphorylation sites in eukaryotic proteins by applying a neural network method 
that recognizes the amino acid patterns around the phosphorylated residue. Each colour-
coded diagram depicts predicted S/T/Y phosphorylation sites according to NetPhos 
algorithm in relation with the protein amino acid sequence. Schematic organization of 
functional domains is shown with experimentally-determined phosphorylation sites (see 
Table 2 for a description of the experimental context). Dashed boxes representing high-
probability areas of phosphorylation are depicted with respect to functional domains. 
PARG’s isoelectric points are estimated for the N-terminal putative regulatory domain, the 
acidic region and the catalytic C-terminal domain. N: amino-terminal, C: carboxy-terminal, 
ZF: zinc fingers, NLS: nuclear localization signal, NES: nuclear export signal, MLS: 
mitochondrial localization signal, AMD: automodification domain, LZM : putative leucine 
zipper-like motif, PADR: Poly(ADP-ribose) polymerases-associated domain, BRCT : 
BRCA1 carboxy-terminal domain, PS: PARP signature, PRD: PARP regulatory domain, 
WGR: tryptophan(W)-glycine(G)-arginine(R) domain.  
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Fig. 2. In vitro phosphorylation of recombinant PARP-1 and PARG. Kinase assays 
consisted of incubating purified PARP-1 and PARG with the protein kinase in the presence 
of [γ-32P]ATP as described in Materials and Methods. The reaction products were separated 
by SDS-PAGE, dried and autoradiographied. (A)  PARP-1 is phosphorylated by PKC 
α and β. (B)  PARP-1 is phosphorylated by various kinases suspected to be involved in 
PARP-1-dependent pathways. (C) PARG is a substrate of CKII. In vitro phosphorylation of 
PARG by CKII was assayed in presence of [γ-32P]ATP. The corresponding coomassie blue-
stained PARG protein band is shown under each lane. 
 
Fig 3. Tandem mass spectrum of a representative PARP-1 tryptic phosphopeptide. Purified 
recombinant PARP-1 expressed in SF-9 cells was digested with trypsin and the resulting 
peptide mixture was enriched in phosphopeptides using titanium dioxide (TiO2). Analysis 
was performed on a LTQ linear ion trap mass spectrometer. MS/MS spectra were assigned 
with Sequest using a two-pass approach as described in Materials and Methods. Scaffold 
was used to filter MS/MS-based identifications and annotate MS/MS spectra. The spectrum 
shows the phosphopeptide GGpSDDSSKDPIDVNYEK which contains a phosphoserine 
residue (S782) identified by the analysis of the peptide’s y and b fragments. An MS/MS 
peptide fragmentation table of y and b ions is shown under the spectrum. The prominent 
neutral loss of a phosphate group (-98 Da) from the phosphopeptide precursor is indicated 
by a green arrow. Sequest: XCorr = 4.85, deltaCn = 0.11;  Ascore = 53.3. See 
Supplementary Information for zoomed regions of the spectrum. 
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Fig 4. Structural models of PARP-1 domains. Schematic representations of PARP-1 
domains that contain phosphoresidues are illustrated. Alpha helices (cyan and green) and β-
sheets are rendered as solid ribbons. Phosphorylation sites identified by MS analysis are 
indicated by an arrow. (A) The first zinc-finger domain of PARP-1 (Protein Data Bank 
(PDB) accession code 2DMJ) is depicted with the homologous zinc-finger of DNA ligase 
III (1UW0). Side chains of amino acid residues that were shown to be required for DNA-
binding in the corresponding extended loop of DNA ligase III zinc finger are labelled in 
green. Structure was modelled after that proposed by Kulczyk et al.76. The position of the 
zinc atom is depicted by a black sphere. (B) The second zinc-finger of PARP-1 (2CS2) is 
modelled in the same orientation as the first zinc-finger. (C)  Schematic representation of 
PARP-1 dimer interface in the third zinc-finger (2RIQ) as proposed by Langelier et al.77. 
(D)  Homologuous BRCT domains of PARP-1 (2COK) and XRCC1 (1CDZ) are modelled 
according to Zhang et al.88. Point mutations (V584D and I585D) in the BRCT domain of 
XRCC1 that disrupt protein-protein interactions are shown in green. (E) The WGR domain 
(2CR9) of PARP-1. (F)  The C-terminal catalytic domain of PARP-1 (1WOK) complexed 
with an inhibitor (black sticks). 
 
Fig 5. S41 Erk-1 phosphorylation site located in the first zinc finger motif of PARP-1 
reveals altered recruitment kinetics at sites of DNA damage following laser 
microirradiation. The spatial dynamics of GFP-tagged single and triple glutamate- and 
aspartate-substituted derivatives that mimic a permanently phosphorylated protein (S27D-
S32E-S41E) were investigated by micro irradiation-induced DNA damage using a 750-nm 
titanium-sapphire laser. The relative fluorescence intensity at the microirradiated region of 
 41
HeLa cells was normalized and plotted as a function of time after integrating data from at 
least five low-expressing cells. The error bars represent the standard error.  
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Table 1. Phosphopeptides detected by mass spectrometry analysis of tryptic digests of 
PARP-1 and PARG. The probability of correct peptide identification is reflected by either 
Sequest’s XCorr and deltaCn (dCn) scores (MS/MS identifications) or the mass difference 
δm between the observed and theoretical peptide mass (MALDI-TOF MS observations). 
Ascore values are reported for phosphopeptides identified by MS/MS when there is more 
than one possible site of phosphorylation within the peptide. Ascore values lower than 20 
indicate that the site of phosphorylation cannot be confidently assigned. In those cases: all 
the possible sites, given the observed MS/MS spectrum, are listed in the “Phosphorylated 
residue(s)” column separated by “or”; and the XCorr and deltaCn scores of the 
corresponding phosphopeptides are reported. When there are many deltaCn scores for a 
peptide, all values but the last thus correspond to XCorr differences between the possible 
phosphopeptides whereas the last value corresponds to the XCorr difference between the 
last possible phosphopeptide and the next Sequest peptide-spectrum match. See 
Supplementary information for detailed analysis of each peptide-spectrum match. 
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Phosphopeptide 
Identified by MS/MS  
(LC-ESI-LTQ) 
Observed by MS 
 (MALDI-TOF)  
Kinase 
Sequence Phosphorylated residue(s) 
Sequest 
Xcorr 
Sequest 
dCn 
Ascore 
δm 
(Da) 
PARP-1 
KCSESIPKDpSLR S32 - - - -0.16 
KVCpSpTNDLK S257 or T258 3.28, 2.78 0.15, 0.90 11.5 - 
KVCpSpTNDLKELLIFNK S257  or  T258  4.50, 4.17 0.07, 0.80 13.3 - 
KEWVpTPKEFR T335 - - - -0.09 
IFPPETSASVAApTPPPpSpTApSAPAAVNS
SASADKPLSNMK T
368 or S372 or T373 or S374 4.35, 4.34, 4.27, 4.24 
0.003, 0.02, 
0.03, 0.12 8.9 - 
Endo-
genous 
GGpSDDSSKDPIDVNYEK S782 4.85 0.11 53.3 -0.53 
MAIMVQpSPMFDGK S41 4.21 0.46 N/A - 
NREELGFRPEYpSASQLK S177   2.89, 2.89 0.003, 0.21 0 (explained in Suppl. data) - 
KVCpSpTNDLKELLIFNK S257  or  T258  3.85, 3.65 0.05, 0.66 0 - 
VCpSpTNDLKELLIFNK S257  or  T258 3.10, 2.85 0.08, 0.49 9.3 - 
IFPPETSASVAApTPPPpSpTApSAPAAVNS
SASADKPLSNMK T
368 or S372 or T373 or S374 4.30, 4.18, 4.18, 4.17 
0.03, 0.03, 
0.03, 0.17 16.1 - 
LGGKLpTGpTANK T420 or T422 3.62, 3.04 0.16, 0.54 14.4 - 
VVpSEDFLQDVSASTK S455 3.96 0.71 53.8 - 
GGAAVDPDSGLEHpSAHVLEK S542 3.85 0.88 21.1 - 
KLpTVNPGTK T656 1.96 0.77 22.9 - 
Erk1 
GGpSDDpSpSKDPIDVNYEK S782 and (S785 or S786) 5.46, 4.85 0.11, 0.26 48.3, 11.5 - 
SGAALpSKK S504 1.51 0.67 75.5 - 
GQVKEEGINKpSEKR S519 3.92 0.43 N/A - PKCβ 
KLpTVNPGTK T656 2.45 0.74 21.2 - 
KVCpSpTNDLK S257 or T258 2.24, 2.05 0.08, 0.64 0 - 
CaMK-II 
GGpSDDpSpSKDPIDVNYEK S782 and (S785 or S786) 5.04, 4.79 0.05,0.13 28.3, 11.5 - 
KVCpSpTNDLKELLIFNK S257  or  T258  5.29, 4.97 0.06, 0.85 13.5 - 
JNK1 
GGpSDDSSKDPIDVNYEK S782 5.43 0.99 32.4 - 
CDK5 GGpSDDpSpSKDPIDVNYEK S782 or S785 or S786 4.56, 4.12, 3.96 
0.10, 0.13, 
0.91 13.49 - 
PARG       
SPQNDDHpSDpTDSEENRDNQQFLTTVK S197 and T199 4.93 0.11 23.2, 29.9 - 
QESCLGNSPPFEKEpSEPESPMDVDNSK S298 4.97 0.10 26.3 - 
SCDPGEDCASCQQDEIDVVPEpSPLpSDV
GSEDVGTGPK S
261 or S264 2.72, 2.63  0.03, 0.11  0 - 
NSCQDpSEADEETSPGFDEQEDGSSSQTA
NKPSR S
316 6.29 0.14 23.4 - 
LYPFIYHAVEpSCAEpTADHSGQR S962 or T966 3.97, 3.76 0.05, 0.10 7.7 - 
CKII 
HpTEQLLEpSEPQpTVTLVPEQFSNANIDR T
164 or S170 or T174 3.50, 3.50, 3.25  
0.00, 0.01, 
0.08 5.1 - 
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Table 2. Prediction-aided interpretation of the phosphorylation sites identified by mass 
spectrometry. Each phosphorylation site is listed with corresponding kinase-specific 
predictions from Phoscan and NetphosK as described in Materials and Methods. The 
phosphorylation sites listed include the PARP-1 and PARG phosphoresidues identified in 
this study as well as those reported in the literature. The predicted phosphorylation potential 
for each phosphoresidue is also displayed (see Supplementary Table S1 for a complete 
score listing). 
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For each phosphorylation experiment: 
 Phosphorylation sites as revealed by either MS/MS 
(black rectangle) or MALDI-TOF MS (gray 
rectangle). (« x » : reported in the litterature) 
Phospho-rylated 
residue(s) 
Endo-
genous Erk1 CKII PKCβ 
CaMK
-II JNK1 CDK5 
Phoscan   
kinase 
prediction 
Netphosk 
kinase 
prediction 
Phospho-
rylation 
potential 
References 
PARP-1 
S32        PKA, PKC Not predicted High This study 
S41        CDK, MAPK CDK5, p38MAPK Low This study 
S177         Not predicted Not predicted Low This study 
S179 X       ATM, DNA-PK ATM, DNA-PK, CDC2 Low Matsuoka et al.
89 
S257  or  T258         CaMK-II / Not predicted Not predicted / PKC High / Low This study 
T335        CDK, MAPK CKII High This study  
T368 or S372 or T373 or 
S375 
 
X 
     
CDK, MAPK / 
DNA-PK / MAPK / 
Not predicted  
GSK3, CDC2, 
CDK5, p38MAPK / 
Not predicted / Not 
predicted / Not 
predicted  
High / High / Low / 
Low 
This study and 
Kauppinen et al.18 
T420 or T422        PKC / PKC PKC / PKC Low / Low This study  
S455        PKA, CKII, AMP-K RSK Low This study  
S504        PKC PKC High This study  
S519        PKC PKC High This study  
S542        Not predicted Not predicted Low This study  
T656        PKA, PKC PKC Low This study 
Y775 X       Not predicted Not predicted Low Rush et al.90 
S782        PKA, CKII, CaMK-
II, MAPKAP-2 PKA High This study  
S782 and (S785 or S786) 
       PKA, CKII, CaMK-
II, MAPKAP-2 / Not 
predicted / Not 
predicted 
PKA / CDC2 / 
CDC2, CKII High / High / High This study 
S782 or S785 or S786 
       PKA, CKII, CaMK-
II, MAPKAP-2 / Not 
predicted / Not 
predicted 
PKA / CDC2 / 
CDC2, CKII High / High / High This study 
PARG 
S22 X       CDK, MAPK CDK5, GSK3 High Beausoleil et al.49 
S137 X       MAPK CDK5, GSK3 High Villen et al.48 
S139 X       PKC, CaMK-II, DNA-PK PKC High Imami et al. 
50 
T164 or S170 or T174        CKII / Not predicted / Not Predicted 
CKII / CKI, CDC2 / 
Not predicted Low / High / Low This study  
S197 and T199        CKII / CKII CKII / CKII High / High This study  
S261 and S264  X       MAPK, ERK / CKII P38MAPK,GSK3 / CKI High / High Villen et al.
48 
S261 or S264        MAPK, ERK / CKII P38MAPK,GSK3 / High / High This study  
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CKI 
S298        CKII CKII, PKG High This study   
S316        CKII CKII High This study + Beausoleil et al.47 
S962 or T966        Not predicted / Not predicted 
CKII / Not 
predicted High / Low This study  
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Table of contents 
 
Phosphorylation is a very 
common posttranslational 
modification event known to 
modulate a wide range of 
biological responses. Beyond 
the regulation of protein 
activity, the interrelation of 
phosphorylation with other 
posttranslational mechanisms is 
responsible for the control of 
diverse signaling pathways. 
Several observations suggest 
that phosphorylation of 
poly(ADP-ribose) polymerase 1 
(PARP-1) regulates its activity. 
There is also accumulating evidence to suggest the establishment of phosphorylation-
dependent assembly of PARP-1-associated multi-protein complexes. Although it is 
relatively straightforward to demonstrate phosphorylation of a defined target, identification 
of the actual amino acids involved still represents a technical challenge for many 
laboratories. Using a combination of bioinformatics-based predictions tools for generic and 
kinase-specific phosphorylation sites, in vitro phosphorylation assays and mass 
spectrometry analysis, we investigated the phosphorylation profile of PARP-1 and 
poly(ADP-ribose) glycohydrolase (PARG), two major enzymes responsible for poly(ADP-
ribose) turnover. Mass spectrometry analysis revealed the phosphorylation of several 
serine/threonine residues within important regulatory domains and motifs of both enzymes. 
Using in vivo microirradiation-induced DNA damage, we show that altered 
phosphorylation at specific sites can modify the dynamics of assembly and disassembly of 
PARP-1 at sites of DNA damage. By documenting and annotating a collection of known 
and newly identified phosphorylation sites, this targeted proteomics study significantly 
advances our understanding of the roles of phosphorylation in the regulation of PARP-1 
and PARG. 
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Supplementary mass spectrometric data 
 
 
 
 
Legend for MS/MS spectra’s fragmentation tables 
• Red background: observed singly-charged (+1) and doubly-charged (+2) b ions. 
• Blue background: observed +1 and +2 y ions. 
• Green background: b and y ions with either a water (-H20) or ammonia (-NH3) loss. 
• “C+57”: carboxyamidomethylated cysteine 
• “M+16”: Oxidized methionine. 
• “S+80”, “T+80”, “Y+80”:  phosphorylated serine, threonine, tyrosine.   
 
 
 
 
Legend for MS/MS spectra 
 
Peptide sequence:  
• The top line corresponds to b ions and the second line to y ions.  
• When two consecutive singly  b (y) ions are observed, the amino acid corresponding to the mass difference is 
shown in red (blue).  
 
MS/MS spectrum: 
• Phosphate neutral loss is flagged by “-98”.  
• Red lines correspond to observed +1 and +2 b ions, and blue lines to observed +1 and +2 y ions.  
• b and y ions with a loss of either a water (-H20) ammonia (-NH3), or phosphate (-H3PO4) are depicted by green 
vertical lines. The parent (precursor) ion as well as a and x ions, with or without loss, are also depicted as green 
vertical lines.  
• “+2H” and “+3H” indicate doubly and triply charged ions respectively.  
• “+1”, “+2”, and “+3” indicates a match to the second, third, or fourth peak of the theoretical isotopic envelope of 
the fragment ion. The LTQ does not resolve the isotopic envelope of the fragment ions and, in the case of heavy 
fragments, the centroided (average) mass can be significantly higher than the monoisotopic mass and lead to a 
match 1 to 3 Da higher than the monoisotopic mass. 
• Black vertical lines indicate unidentified MS/MS fragments. 
Please use the hyperlink in the “Sequence” and “δm” columns to directly access the 
peptide’s MS supplementary data  
 
Phosphopeptide 
Identified by MS/MS  
(LC-ESI-LTQ) 
Observed by MS 
 (MALDI-TOF)  
Kinase 
Sequence Phosphorylated residue(s) 
Sequest 
Xcorr 
Sequest 
dCn 
Ascore 
δm 
(Da) 
PARP-1 
KCSESIPKDpSLR S32 - - - -0.16 
KVCpSpTNDLK S257 or T258 3.28, 2.78 0.15, 0.90 11.5 - 
KVCpSpTNDLKELLIFNK S257  or  T258  4.50, 4.17 0.07, 0.80 13.3 - 
KEWVpTPKEFR T335 - - - -0.09 
IFPPETSASVAApTPPPpSpTApSAPAAVNS
SASADKPLSNMK T
368 or S372 or T373 or S374 4.35, 4.34, 4.27, 4.24 
0.003, 0.02, 
0.03, 0.12 8.9 - 
Endo-
genous 
GGpSDDSSKDPIDVNYEK S782 4.85 0.11 53.3 -0.53 
MAIMVQpSPMFDGK S41 4.21 0.46 N/A - 
NREELGFRPEYpSASQLK S177   2.89, 2.89 0.003, 0.21 0 (explained in Suppl. data) - 
KVCpSpTNDLKELLIFNK S257  or  T258  3.85, 3.65 0.05, 0.66 0 - 
VCpSpTNDLKELLIFNK S257  or  T258 3.10, 2.85 0.08, 0.49 9.3 - 
IFPPETSASVAApTPPPpSpTApSAPAAVNS
SASADKPLSNMK T
368 or S372 or T373 or S374 4.30, 4.18, 4.18, 4.17 
0.03, 0.03, 
0.03, 0.17 16.1 - 
LGGKLpTGpTANK T420 or T422 3.62, 3.04 0.16, 0.54 14.4 - 
VVpSEDFLQDVSASTK S455 3.96 0.71 53.8 - 
GGAAVDPDSGLEHpSAHVLEK S542 3.85 0.88 21.1 - 
KLpTVNPGTK T656 1.96 0.77 22.9 - 
Erk1 
GGpSDDpSpSKDPIDVNYEK S782 and (S785 or S786) 5.46, 4.85 0.11, 0.26 48.3, 11.5 - 
SGAALpSKK S504 1.51 0.67 75.5 - 
GQVKEEGINKpSEKR S519 3.92 0.43 N/A - PKCβ 
KLpTVNPGTK T656 2.45 0.74 21.2 - 
KVCpSpTNDLK S257 or T258 2.24, 2.05 0.08, 0.64 0 - 
CaMK-II 
GGpSDDpSpSKDPIDVNYEK S782 and (S785 or S786) 5.04, 4.79 0.05,0.13 28.3, 11.5 - 
KVCpSpTNDLKELLIFNK S257  or  T258  5.29, 4.97 0.06, 0.85 13.5 - 
JNK1 
GGpSDDSSKDPIDVNYEK S782 5.43 0.99 32.4 - 
CDK5 GGpSDDpSpSKDPIDVNYEK S782 or S785 or S786 4.56, 4.12, 3.96 
0.10, 0.13, 
0.91 13.49 - 
PARG       
SPQNDDHpSDpTDSEENRDNQQFLTTVK S197 and T199 4.93 0.11 23.2, 29.9 - 
QESCLGNSPPFEKEpSEPESPMDVDNSK S298 4.97 0.10 26.3 - 
SCDPGEDCASCQQDEIDVVPEpSPLpSDV
GSEDVGTGPK S
261 or S264 2.72, 2.63  0.03, 0.11  0 - 
NSCQDpSEADEETSPGFDEQEDGSSSQTA
NKPSR S
316 6.29 0.14 23.4 - 
LYPFIYHAVEpSCAEpTADHSGQR S962 or T966 3.97, 3.76 0.05, 0.10 7.7 - 
CKII 
HpTEQLLEpSEPQpTVTLVPEQFSNANIDR T
164 or S170 or T174 3.50, 3.50, 3.25  
0.00, 0.01, 
0.08 5.1 - 
 
Supplementary mass spectrometric data: 
PARP-1, endogenous phosphorylation 
 
 
 
 
Spectrum Parp_TiO2_20061213.4843.4843.2.dta (charge state: +2) 
 
b2 b3 b4 b5 b6 b7 b8
K V C pS T N D L K
y8 y7 y6 y5 y4 y3 y2  
 
 
Sequest: XCorr = 3.28, dCn1 = 0.15 (between 1st and 2nd best matches), dCn2 = 0.90 (between 2nd and 3rd best matches).  
 
Ascore = 11.51. 
 
Sequest’s second best match with XCorr = 2.78 is to the same peptide sequence but with an alternative phosphorylation site: 
KVCSpTNDLK.  
 
The weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+2H-98
b2
y2
y3b3 y4
b4
y5
b5 y6b6
b7
y7
b8
y8
K V C+57 S+80 T N D L K
K L D N T S+80 C+57 V K
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 200 400 600 1000
1 144,39 AMU, +2 H (Parent Error: 770 ppm)
800
 
 
 
 
Close to precursor 
 
parent+2H-98
T
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
100%
500 510 520 530 540 550
1 144,39 AMU, +2 H (Parent Error: 770 ppm)
Left of precursor 
 
b4-98
y9-NH3-98+2H
parent+2H-NH3-98
y2
b2
y3
b3
y4
C+57 S+80
D N
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
8,0%
10,0%
225 250 275 300 325 350 375 400 425 450 475 500
1 144,39 AMU, +2 H (Parent Error: 770 ppm)
 
 
 
 
Right of precursor 
 
b4+0
b7-98
b7+1
parent+2H-NH3
b4
y5
b5
y6 b6
b7
y7
b8
y8
T N D L
T S+80 C+57 V
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
15,0%
17,5%
20,0%
600 700 800 1000
1 144,39 AMU, +2 H (Parent Error: 770 ppm)
900
 
 
  
Spectrum 8372.4191.4191.3.dta (charge state: +3) 
 
b3 b4 b5 b6 b7 b8 b9 b11 b12 b13 b14 b15
K V C pS T N D L K E L L I F N K
y15 y14 y13 y12 y10 y9 y8 y7 y6 y5 y4 y3 y2  
 
Sequest: XCorr = 4.50, dCn1 = 0.07 (between 1st and 2nd best matches), dCn2 = 0.80 (between 2nd and 3rd best matches).  
 
Ascore = 13.27. 
 
Sequest’s second best match with XCorr = 4.17 is to the same peptide sequence but with an alternative phosphorylation site: 
KVCSpTNDLKELLIFNK.  
 
The weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
y9+2H
parent+3H+1-98
y2 b3y3
y4
b4
b5
y6b6
y7
b7
b8
y8 b9
K V C+57 S+80 T N D L K E L L I F N K
K N F I L L E K L D N T S+80 C+57 V K
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750 2000
2 002,20 AMU, +3 H (Parent Error: 600 ppm)
 
 
 
 
Close to precursor 
 
parent+3H+1-98
b5
T
L
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
600 620 640 680
2 002,20 AMU, +3 H (Parent Error: 600 ppm)
660
Left of precursor 
 
y9+2H
parent+3H-H2O
parent+3H-NH3
y2 b3
y3
y4
b4
C+57 S+80 T
F I L
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
10%
20%
300 350 400 450 500 550 600
2 002,20 AMU, +3 H (Parent Error: 600 ppm)
 
 
 
 
Right of precursor 
 
y6-NH3-NH3
y12+2H
a6
b7-98
y14-196+2H
b13+2H
b14+2H
y7+1
b15-98+2H
b7+1
y14+2H
y14+2H+1
b8-98
y15+2H
b8+1
b7
b8
b5
y6 b6
y7
y8 b9
N D L K
L E K L
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
700 800 900 1100
2 002,20 AMU, +3 H (Parent Error: 600 ppm)
1000
 
 
  
 
 
Spectrum Parp_TiO2_20061213.6526.6526.3.dta (charge state: +3) 
 
b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16 b17 b18 b20 b24 b25 b27 b31 b35 b37 b39
I F P P E T S A S V A A pT P P P S T A S A P A A V N S S A S A D K P L S N M K
y37 y36 y35 y34 y33 y31 y30 y29 y28 y27 y25 y24 y23 y22 y21 y20 y19 y18 y16 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6 y4 y3  
 
Sequest: XCorr = 4.35, dCn1 = 0.003 (between 1st and 2nd best matches), dCn2 = 0.02 (between 2nd and 3rd best matches), 
dCn3 = 0.03 (between 3rd and 4th best matches), 0.12 dCn4 = (between 4th and 5th best matches).  
 
Ascore = 8.92. 
 
Sequest’s second, third and fourth  best matches with XCorr = 4.34. 4.27 and 4.24 respectively are to the same peptide sequence 
but with alternative phosphorylation sites:  
IFPPETSASVAATPPPpSTASAPAAVNSSASADKPLSNMK 
IFPPETSASVAATPPPSpTASAPAAVNSSASADKPLSNMK 
IFPPETSASVAATPPPSTApSAPAAVNSSASADKPLSNMK 
 
The weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could be either of the 
above four (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
Note: Base peak (m/z 1202.6) is y37+3H (PPETSASVAATPPPpSTASAPAAVNSSASADKPLSNMK, theoretical m/z of 1201.9) and is not 
unexpected since fragments with N-terminal proline are typically very intense. It was not identified by the visualisation software (Scaffold) because 
it does not handle triply-charged fragments. Simarly, the unidentified fragment at m/z 1170 is y36+3H, another fragment with an N-terminal proline. 
 
Full-range  
 
1 202,6?
parent+3H+1-98
parent+3H+4-98
y3 y4 b5 y6b7y7b8 b9y8 y9b10b11y10b12y11y12y13b b14y 4b15y15 b17
y18
y20
I F P P E T S A S V A A T+80 P P P S T A S A P A A V N S S A S A D K P L S N M+16 K
K M+16 N S L P K D A S A S S N V A A P A S A T S P P P T+80 A A V S A S T E P P F I
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0 500 1000 1500 2000 2500 3000 3500
3 863,65 AMU, +3 H (Parent Error: 210 ppm)
 
 
 
 
Close to precursor 
 
1 202,6?
parent+3H+1-98
parent+3H+4-98
b12 y11 y12 y13b13
T+80
S S
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3 863,65 AMU, +3 H (Parent Error: 210 ppm)
Left of precursor 
 
a9
b10-H2O-H2O
b20+2H
b25-H2O-H2O+2
b25-H2O+2
y3 y4 b5
y6
b7
y7
b8
b9 y8
y9
b10
b11
y10
b12
y11
P E T S A S V A A
S L P K D A S A
m/z
R
el
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e 
In
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ity
0,0%
2,0%
4,0%
6,0%
8,0%
10,0%
400 500 600 700 800 900 1100
3 863,65 AMU, +3 H (Parent Error: 210 ppm)
1000
 
 
 
 
Right of precursor 
 
y28+2H
y29+2H
y29+2H+1
y36+2H
y37+2H
y13
b13
b14y14
b15
y15 b17
y18
y20
P P P S T A S
S N V A A P A S
m/z
R
el
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iv
e 
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ity
0,0%
2,0%
4,0%
6,0%
8,0%
1300 1400 1500 1600 1700 1900
3 863,65 AMU, +3 H (Parent Error: 210 ppm)
1800
 
 
  
 
Spectrum Parp_TiO2_20061213.6194.6194.3.dta (charge state: +3) 
 
b3 b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16
G G pS D D S S K D P I D V N Y E K
y16 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6 y5 y4 y3 y2  
 
Sequest: XCorr = 4.85, dCn = 0.11. 
Ascore = 53.29 
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
y8+2H
b11-98+2H y6+1
parent+3H+3-98
y2b3 b4 y3
b5 y4
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y5
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y8 b10 y9 b11 b12
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Close to precursor 
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Left of precursor 
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1 906,67 AMU, +3 H (Parent Error: 1000 ppm)
 
 
 
 
Right of precursor 
 
y12+2H
y13+2H
y6+1
y5
y6
b7
b8
y7
b9
y8
b10 y9 b11 b12
S K D P I D
D I P D K S
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
10%
20%
30%
700 800 900 1000 1200
1 906,67 AMU, +3 H (Parent Error: 1000 ppm)
1100
 
 
  
 
  
MALDI-TOF MS spectrum  
 
 
Full range 
 
 
 
First partial (zoomed) spectrum showing resolved isotopic envelopes 
 
KEWVpTPKEFR 
Theoretical MH+ (monoisotopic): m/z 1399.68 
Observed MH+(monoisotopic): m/z 1399.61 
δm = - 0.09 Th 
 
KCSESIPKDpSLR 
Theoretical MH+ (monoisotopic): m/z 1499.69 
Observed MH+(monoisotopic): m/z 1499.53 
δm = - 0.16 Th 
 
 
 
Second partial (zoomed) spectrum showing resolved isotopic envelopes 
 
GGpSDDSSKDPIDVNYEK  
Theoretical MH+ (monoisotopic): m/z 1905.78 
Observed MH+(monoisotopic): m/z 1905.25 
δm = - 0.53 Th 
 
 
 
 
Supplementary mass spectrometric data: 
PARP-1, phosphorylated by extracellular signal-regulated kinase-1 (ERK-1) 
 
 
 
Spectrum 7674.3412.3412.2.dta (charge state: +2) 
 
b3 b4 b5 b6 b7 b8 b9 b10 b11 b12
M A I M V Q pS P M F D G K
y11 y10 y9 y8 y7 y5 y4 y3  
 
Sequest: XCorr = 4.21, dCn = 0.46. 
Ascore = Not available (only one possible phosphorylation site). 
 
The phosphorylation is located at the only possible phosphorylation site (no other S, T, Y within the peptide). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+2H-H2O-162
parent+2H-98
parent+2H+2-98
parent+2H+1-64
y3
b3
y4b4
b5
y5
b6
y7
b7
b8
y8
y9
b9
y10
b10
y11
b11
b12
M+16 A I M+16 V Q S+80 P M F D G K
K G D F M P S+80 Q V M+16 I A M+16
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 200 400 600 800 1000 1400
1 566,67 AMU, +2 H (Parent Error: 660 ppm)
1200
 
 
 
 
Close to precursor 
 
parent+2H-H2O-162
parent+2H-98
parent+2H+2-98
parent+2H+1-64
b6
S+80
S+80
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
660 680 700 720 740 760 780 800
1 566,67 AMU, +2 H (Parent Error: 660 ppm)
Left of precursor 
 
b6+1
parent+2H-H2O-162
parent+2H-NH3-162
parent+2H-162
y3
b3
y4
b4
b5
y5
b6
M+16 V Q
F M P
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
5,0%
10,0%
15,0%
20,0%
350 400 450 500 550 600 650 700
1 566,67 AMU, +2 H (Parent Error: 660 ppm)
 
 
 
 
Right of precursor 
 
y7+1
b8+1
b8+2
y9+1
y10+1
y10+2
y7
y10
b7
b8
y8
y9
b9
b10
y11
b11
b12
S+80 P M F D G
Q V M+16 I A
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
10%
20%
30%
800 900 1000 1100 1200 1300 1400
1 566,67 AMU, +2 H (Parent Error: 660 ppm)
 
 
Spectrum  7860.4386.4386.3.dta (charge state: +4) 
 
b3 b4 b5 b6 b7 b8 b9 b10 b11 b13 b14 b15
K V C pS T N D L K E L L I F N K
y15 y14 y13 y10 y9 y8 y7 y6 y5 y4 y3 y2  
 
Sequest: XCorr = 3.85, dCn1 = 0.05 (between 1st and 2nd best matches), dCn2 = 0.66 (between 2nd and 3rd best matches).  
Ascore = 0. 
 
Sequest’s second best match with XCorr = 3.65 is to the same peptide sequence but with an alternative phosphorylation site: 
KVCSpTNDLKELLIFNK.  
 
The very weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
y9+2H
parent+3H-98
parent+3H+1-98
y2 b3
y3
y4
y5
b5 y6
y7
b7
b8
y8
b9
K V C+57 S T+80 N D L K E L L I F N K
K N F I L L E K L D N T+80 S C+57 V K
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750 2000
2 002,67 AMU, +3 H (Parent Error: 830 ppm)
 
 
 
 
Close to precursor 
 
parent+3H-98
parent+3H+1-98
y5
b5
L
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
600 620 640 660 700
2 002,67 AMU, +3 H (Parent Error: 830 ppm)
680
Left of precursor 
 
y8+2H
y9+2H
parent+3H-NH3-
y2 b3
y3
y4
y5
C+57 S T+80
F I L
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
10%
20%
30%
40%
300 350 400 450 500 550 600
2 002,67 AMU, +3 H (Parent Error: 830 ppm)
 
 
 
 
Right of precursor 
 
c11-98+2H
a6-98
y6+1
y12-NH3+2H+1
a13-H2O+2H
b7-98
b13+2H
b14-98+2H y7+1
y7+2
b15-98+2H
b7+1
y14+2H
b8-98
x15-98+2H
y15+2H b8+1
b7
b8
b5
y6
y7
y8
b9
N D L K
L E K L
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
15,0%
17,5%
20,0%
700 800 900 1100
2 002,67 AMU, +3 H (Parent Error: 830 ppm)
1000
 
Spectrum  7674.4649.4649.2.dta (charge state: +2) 
 
b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14
V C pS T N D L K E L L I F N K
y13 y12 y11 y10 y9 y8 y7 y6 y5 y4 y3  
 
Sequest: XCorr = 3.10, dCn1 = 0.08 (between 1st and 2nd best matches), dCn2 = 0.49 (between 2nd and 3rd best matches).  
Ascore = 9.34. 
 
Sequest’s second best match with XCorr = 2.85 is to the same peptide sequence but with an alternative phosphorylation site: 
VCSpTNDLKELLIFNK.  
 
The very weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
b7-NH3-H2O
a7
parent+2H-98
parent+2H+1-98
y3
y4b4 y5b5 b6
b7
y7 b8y
y9
b9 y10 y11
b11 y12
b12
b13
V C+57 S+80 T N D L K E L L I F N K
K N F I L L E K L D N T S+80 C+57 V
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750
1 873,47 AMU, +2 H (Parent Error: 300 ppm)
 
 
 
 
Close to precursor 
 
b7-NH3-H2O
a7
parent+2H-98
parent+2H+1-98
b7
y7
L K
E K
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
825 850 875 900 925 950 975
1 873,47 AMU, +2 H (Parent Error: 300 ppm)
Left of precursor 
 
y12+2H
b7-NH3-H2O
a7
y3
y4b4
y5b5 b6
b7
y7
T N D L
I L L E
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
400 500 600 800
1 873,47 AMU, +2 H (Parent Error: 300 ppm)
700
 
 
 
 
Right of precursor 
 
a15-NH3+2H
b15-H2O-H2O+2H
b15-NH3-NH3+2H
a15+2H
b8-H2O
b9-NH3
y9+1
y10-NH3
y11-H2O
b12-98
b12+1
b12+2
b13-H2O-98
y13-NH3-98
b8y8
y9
b9
y10
y11
b11
y12
b12
b13
K E L L I F
K L D N T S+80
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
1000 1100 1200 1300 1400 1500 1600
1 873,47 AMU, +2 H (Parent Error: 300 ppm)
 
 
Spectrum 7674.3311.3311.3.dta (charge state: +3) 
 
b2 b3 b4 b5 b6 b7 b8 b9 b10 b12 b13 b14 b15 b16
N R E E L G F R P E Y pS A S Q L K
y15 y14 y13 y12 y10 y9 y8 y7 y5 y4 y3 y2  
 
Sequest: XCorr = 2.89, dCn1 = 0.003 (between 1st and 2nd best matches), dCn2 = 0.21 (between 2nd and 3rd best matches).  
Ascore = 0. 
 
Sequest’s second best match with XCorr = 2.89 is to the same peptide sequence but with an alternative phosphorylation site: 
NREELGFRPEpYSASQLK.  
 
The very weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). However, since a strong neutral loss of the 
phosphate ion is observed, the phosphotyrosine peptide can be ruled out since phosphotyrosine do not undergo neutral 
loss. 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+3H+3-98
y2b2 y3b3 y4 b4y5 b5 b7y7 b8 y9 b10
N R E E L G F R P E Y S+80 A S Q L K
K L Q S A S+80 Y E P R F G L E E R N
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750 2000
2 102,48 AMU, +3 H (Parent Error: -240 ppm)
 
 
 
 
Close to precursor 
 
parent+3H+3-98
b5
G
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
640 650 660 670 680 700
2 102,48 AMU, +3 H (Parent Error: -240 ppm)
690
 
Left of precursor 
 
a4
a5
a6-NH3-H2O
y2 b2 y3 b3
y4
b4
y5
b5
E E L
Q S A S+80
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
1,0%
2,0%
3,0%
250 300 350 400 450 500 550 600 650
2 102,48 AMU, +3 H (Parent Error: -240 ppm)
 
 
 
 
Right of precursor 
 
b12-98+2H
y12+2H
y13-98+2H
a12+2H
y7-98y13+2H
a13+2H
b14-98+2H
b14-NH3+2H
b15-NH3-98+2H
b15-98+2H b15-NH3+2H
b15+2H
b15+2H+1
b15+2H+2
b16-98+2H
c16-98+2H
b16-NH3+2H
b16+2H+1
b16+2H
b7
y7
b8
y9
b10
F R P E
Y E P R
m/z
R
el
at
iv
e 
In
te
ns
ity
0,00%
0,50%
1,00%
1,50%
2,00%
2,50%
700 800 900 1000 1200
2 102,48 AMU, +3 H (Parent Error: -240 ppm)
1100
 
 
Spectrum 7674.3346.3346.3.dta (charge state: +3) 
 
b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16 b18 b19 b20 b25 b27 b32 b33 b35 b36 b37 b38 b39
I F P P E T S A S V A A pT P P P S T A S A P A A V N S S A S A D K P L S N M K
y37 y36 y34 y33 y31 y30 y29 y28 y27 y25 y24 y22 y21 y20 y19 y18 y17 y16 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6  
 
Sequest: XCorr = 4.30, dCn1 = 0.03 (between 1st and 2nd best matches), dCn2 = 0.03 (between 2nd and 3rd best matches), 
dCn3 = 0.03 (between 3rd and 4th best matches), 0.17 dCn4 = (between 4th and 5th best matches).  
 
Ascore = 16.10. 
 
Sequest’s second, third and fourth  best matches with XCorr = 4.18, 4.18 and 4.17 respectively are to the same peptide sequence 
but with alternative phosphorylation sites:  
IFPPETSASVAATPPPSpTASAPAAVNSSASADKPLSNMK 
IFPPETSASVAATPPPpSTASAPAAVNSSASADKPLSNMK 
IFPPETSASVAATPPPSTApSAPAAVNSSASADKPLSNMK 
 
The weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could be either of the 
above four (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
Note: Base peak (m/z 1202.6) is y37+3H (PPETSASVAATPPPpSTASAPAAVNSSASADKPLSNMK, theoretical m/z of 1201.9) and is not 
unexpected since fragments with N-terminal proline are typically very intense. It was not identified by the visualisation software (Scaffold) because 
it does not handle triply-charged fragments. Simarly, the unidentified fragment at m/z 1169 is y36+3H, another fragment with an N-terminal proline. 
 
 
Full-range  
 
1 202,3?
parent+3H+1-98
parent+3H+2-98
parent+3H+4-98
b6y6 y7b8 b9y8 y9b10b11y10b12y 1y12y13b b14y b15y15 y18y19b19
I F P P E T S A S V A A T+80 P P P S T A S A P A A V N S S A S A D K P L S N M+16 K
K M+16 N S L P K D A S A S S N V A A P A S A T S P P P T+80 A A V S A S T E P P F I
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 500 1000 1500 2000 2500 3000 3500
3 864,59 AMU, +3 H (Parent Error: 450 ppm)
 
 
 
 
Close to precursor 
 
1 202,3?
parent+3H+1-98
parent+3H+2-98
parent+3H+4-98
y12
T+80
S S
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
1200 1220 1240 1260 1280 1300 1320 1340
3 864,59 AMU, +3 H (Parent Error: 450 ppm)
Left of precursor 
 
a9
b10-H2O-H2O
b20+2H
b6 y6
y7
b8 b9 y8 y9
b10
b11
y10
b12
y11
S A S V A A
P K D A S A
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
8,0%
700 800 900 1100
3 864,59 AMU, +3 H (Parent Error: 450 ppm)
1000
 
 
 
 
Right of precursor 
 
y27-NH3+2H
y27+2H
y27+2H+1
y28+2H+1
y28+2H
y29+2H
y29+2H+1
y14+1
y30+2H
y31+2H
y31+2H+1
y36+2H
y36+2H+1
a18
y13
b13
b14y14 b15
y15
y18
y19 b19
P P P S T A S
S N V A A P A S A
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
1,0%
2,0%
3,0%
4,0%
5,0%
1300 1400 1500 1600 1700 1800 1900 2000
3 864,59 AMU, +3 H (Parent Error: 450 ppm)
 
 
Spectrum  7674.1931.1931.2.dta (charge state: +2) 
 
b2 b3 b4 b5 b6 b7 b8 b9 b10
L G G K L pT G T A N K
y10 y9 y8 y7 y6 y5 y4 y3 y2  
 
Sequest: XCorr = 3.62, dCn1 = 0.16 (between 1st and 2nd best matches), dCn2 = 0.54 (between 2nd and 3rd best matches).  
Ascore = 14.42. 
 
Sequest’s second best match with XCorr = 3.04 is to the same peptide sequence but with an alternative phosphorylation site: 
LGGKLTGpTANK.  
 
The very weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+2H-98
b2 b3 y2 y3 b4 y4 b5
y5
b6y6 b7 y7 b8 b9 y8 y9
b10
y10
L G G K L T+80 G T A N K
K N A T G T+80 L K G G L
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 200 400 600 1000
1 139,21 AMU, +2 H (Parent Error: 550 ppm)
800
 
 
 
 
Close to precursor 
 
parent+2H-98
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
100%
505,0 510,0 515,0 520,0 525,0 530,0 535,0
1 139,21 AMU, +2 H (Parent Error: 550 ppm)
Left of precursor 
 
y9+2H
y9+2H+0y5+0
y5
b2 b3
y2
y3 b4
y4
b5
G K L
N A T G
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
200 250 300 350 400 450 500
1 139,21 AMU, +2 H (Parent Error: 550 ppm)
 
 
 
 
Right of precursor 
 
b6-98
b11-NH3-NH3+2H
parent+2H-H2O
b6 y6
b7
y7
b8
b9
y8 y9
b10
y10
T+80 G T A N
T+80 L K G G
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
15,0%
600 700 800 1000
1 139,21 AMU, +2 H (Parent Error: 550 ppm)
900
 
 
Spectrum  7674.4292.4292.2.dta (charge state: +2) 
 
b4 b5 b6 b8 b9 b10 b11 b12 b13 b14
V V pS E D F L Q D V S A S T K
y13 y12 y11 y10 y9 y8 y7 y6 y5 y3  
 
Sequest: XCorr = 3.96, dCn = 0.71. 
Ascore = 53.75 
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
b15-NH3-H2O+2H
parent+2H-98
parent+2H+1-98
y3
y5
b4 y6b5 y7 b6
y8
y9
y10
b9
y11
b10
b11y12b12
b13 y13
b14
V V S+80 E D F L Q D V S A S T
K T S A S V D Q L F D E S+80 V
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 200 400 600 800 1000 1400
1 704,98 AMU, +2 H (Parent Error: 710 ppm)
1200
 
 
 
 
Close to precursor 
 
b15-NH3-H2O+2H
parent+2H-98
parent+2H+1-98
y7
b6
y8
L
Q L
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
700 725 750 775 800 825 850 875 900
1 704,98 AMU, +2 H (Parent Error: 710 ppm)
Left of precursor 
 
 
y5
b5+1 a12-H2O-H2O+2H
b6-98
b13-98+2H
z13-98+2H
y13-98+2H
y7+1
a14-98+2H
a7-H2O-98
a6
y13-NH3+2H
y13+2H
b14-NH3+2H
b7-98
y14-NH3-H2O+2H
parent+2H-H2
parent+2H-NH
y3
b4
y6
b5
y7
b6
E D F
A S V D Q
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
400 500 700
1 704,98 AMU, +2 H (Parent Error: 710 ppm)
600
 
 
 
Right of precursor 
 
b15-NH3-H2O+2H
y8+1 a8-NH3-H2O b11-98
y8
y9
y10
b9
y11
b10
b11 y12 b12
b13 y13
b14
Q D V S A S T
L F D E S+80 V
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
10%
20%
30%
900 1000 1100 1200 1300 1500
1 704,98 AMU, +2 H (Parent Error: 710 ppm)
1400
 
 
Spectrum  7674.2786.2786.2.dta (charge state: +2) 
 
b5 b6 b8 b10 b11 b12 b13 b14 b15 b16 b17 b18 b19
G G A A V D P D S G L E H pS A H V L E K
y19 y18 y17 y16 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6 y5 y4 y3  
 
Sequest: XCorr = 3.85, dCn = 0.88. 
Ascore = 21.05 
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
y13+2H
a10
parent+2H-H2O-98
parent+2H-98
parent+2H+1-98
b5y3 b6y4 y5 b8y6 y7 b11 y8 b12 b13y10 y11 b14
y12 y13 b16
y14
b17 b18
G G A A V D P D S G L E H S+80 A H V L E K
K E L V H A S+80 H E L G S D P D V A A G G
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750 2000
2 068,24 AMU, +2 H (Parent Error: 150 ppm)
 
 
 
 
Close to precursor 
 
parent+2H-H2O-98
parent+2H-98
parent+2H+1-98
b11 y8 b12
L E
H E
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
900 925 950 975 1000 1025 1050 1075 1100 1125
2 068,24 AMU, +2 H (Parent Error: 150 ppm)
Left of precursor 
 
y13+2H
a10
b5 y3
b6
y4 y5 b8y6
y7
b11
D P D S G L
L V H A S+80 H
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
10%
20%
30%
40%
400 500 600 700 900
2 068,24 AMU, +2 H (Parent Error: 150 ppm)
800
 
 
 
 
Right of precursor 
 
y20-H2O-H2O+2H
y13-H2O-98
y14-98
y14-H2O
y14+1
y8
y14
b12 b13
y10
y11
b14
y12
y13 b16
b17
b18
E H S+80 A H V L
E L G S D P D V
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
15,0%
1000 1100 1200 1300 1400 1500 1600 1700 1800
2 068,24 AMU, +2 H (Parent Error: 150 ppm)
 
 
Spectrum 7674.2061.2061.2.dta (charge state: +2) 
 
b2 b3 b4 b5 b6 b7 b8
K L pT V N P G T K
y8 y7 y6 y5 y4  
 
Sequest: XCorr = 1.96, dCn = 0.77. 
Ascore = 22.88 
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
a3-NH3-98
y9-NH3-NH3+2H
parent+2H-98
parent+2H+1-98
b2 y4 b3
y6
b5
b6 b7y7 b8
y8
K L T+80 V N P G T K
K T G P N V T+80 L K
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 200 400 600 1000
1 036,92 AMU, +2 H (Parent Error: 370 ppm)
800
 
 
 
 
Close to precursor 
 
y9-NH3-NH3+2H
parent+2H-98
parent+2H+1-98
V
N
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
100%
440 460 480 500 520
1 036,92 AMU, +2 H (Parent Error: 370 ppm)
Left of precursor 
 
a3-NH3-98
a4-NH3-H2O
parent+2H-NH3-98
b2
y4
b3
T+80
G P N
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
10%
20%
30%
225 250 275 300 325 350 375 400 425 450
1 036,92 AMU, +2 H (Parent Error: 370 ppm)
 
 
 
 
Right of precursor 
 
y5-NH3+0
y5-NH3
b9-NH3-H2O+2H
b9-NH3-NH3+2H
y9-NH3-NH3+2H
y7-98
y8-98
y6
b5
b6 b7
y7 b8
y8
N P G T
V T+80 L
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
5,0%
10,0%
15,0%
20,0%
25,0%
500 600 700 900
1 036,92 AMU, +2 H (Parent Error: 370 ppm)
800
 
 
Spectrum 7860.2727.2727.2.dta (charge state: +2) 
 
b3 b4 b5 b6 b7 b8 b9 b11 b12 b13 b14 b15 b16
G G pS D D S S K D P I D V N Y E K
y16 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6 y5 y4 y3  
 
Sequest: XCorr = 5.78, dCn = 0.10. 
Ascore = 50.89 
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+2H-NH3-98
parent+2H-98
parent+2H+1-98
b3 b4 y3 b5 y4 b6
y5
b7 y6 b8 y7
b9 y8 y9 b11 y10
b12
y11b13y12 b14y13 b15 b16
G G S+80 D D S S K D P I D V N Y E K
K E Y N V D I P D K S S D D S+80 G G
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750
1 905,17 AMU, +2 H (Parent Error: 210 ppm)
 
 
 
 
Close to precursor 
 
parent+2H-NH3-98
parent+2H-98
parent+2H+1-98
y7
b9
D
P
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
860 880 900 940
1 905,17 AMU, +2 H (Parent Error: 210 ppm)
920
Left of precursor 
 
y5+1
b8-98
y13+2H
y14+2Hb16-98+2H
y15-98+2H
b3 b4
y3 b5
y4
b6
y5
b7
y6
b8
y7
D D S S K D
Y N V D I
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
1,0%
2,0%
3,0%
4,0%
5,0%
300 400 500 600 800
1 905,17 AMU, +2 H (Parent Error: 210 ppm)
700
 
 
 
 
Right of precursor 
 
b9+1
b17-NH3-H2O+2H
y8+1
b11-98
y9+1
b12-98
b12+1
b12+2
b9
y8
y9
b11
y10
b12
y11
b13
y12
b14
y13
b15
b16
P I D V N Y E
P D K S S D D S+80
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
1000 1100 1200 1300 1400 1500 1600 1700
1 905,17 AMU, +2 H (Parent Error: 210 ppm)
 
 
Spectrum 7674.3004.3004.2.dta (charge state: 2) 
 
b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16
G G pS D D pS S K D P I D V N Y E K
y16 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6 y5 y4 y3  
 
Sequest: XCorr = 5.46, dCn1 = 0.11 (between 1st and 2nd best matches), dCn2 = 0.26 (between 2nd and 3rd best matches).  
Ascore = 48.32 (first phosphorylation), 11.51 (second phosphorylation). 
 
Sequest’s second best match with XCorr = 4.85 is to the same peptide sequence but with an alternative phosphorylation site: 
GGpSDDSpSKDPIDVNYEK.  
 
The weak Ascore for the second phosphorylation indicates that, given the observed MS/MS spectrum, the phosphopeptide 
identified could either be Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
b17-98+2H
parent+2H-196
parent+2H+1-196
parent+2H-NH3-98
parent+2H+1-98
b4 y3 b5
y4 y5
b6 y7
b8
y8
b9
y9
b10
b11
y10 y11
b12
b13y12 b14y13 b15 b16
G G S+80 D D S+80 S K D P I D V N Y E K
K E Y N V D I P D K S S+80 D D S+80 G G
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1750
1 986,03 AMU, +2 H (Parent Error: 650 ppm)
1500
 
 
 
 
Close to precursor 
 
b17-98+2H
parent+2H-196
parent+2H+1-196
parent+2H-NH3-98
parent+2H+1-98
y7
b8
y8
b9
D
P
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
875 900 925 950 975 1000 1025
1 986,03 AMU, +2 H (Parent Error: 650 ppm)
Left of precursor 
 
b7-H2O
b7+1
y13+2H+1
y13+2H
b9-196
y14+2H
y14+2H+1c16-98+2H
y15-98+2H
parent+2H-NH3-
b4
y3
b5
y4
y5
b6
y7
D S+80 S K
N V D I
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
8,0%
10,0%
400 500 600 800
1 986,03 AMU, +2 H (Parent Error: 650 ppm)
700
 
 
 
 
Right of precursor 
 
b9-NH3-H2O
y17-H2O-H2O+2H
a11-H2O-196y8+1
y9+1
y9+2b11-98
b11+1b12-98
b13-196
b12+1
b12+2
y8
b9
y9
b10
b11
y10
y11
b12
b13
y12
b14
y13
b15
b16
P I D V N Y E
D K S S+80 D D S+80
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
8,0%
1000 1200 1400 1800
1 986,03 AMU, +2 H (Parent Error: 650 ppm)
1600
 
 
 
 
 
Supplementary mass spectrometric data: 
PARP-1, Protein Kinase C β-phosphorylated 
 
 
 
 
b2 b3 b4 b5 b6 b7
S G A A L pS K K
y7 y6 y5 y4 y3 y2 y1  
 
Sequest: XCorr = 1.51, dCn = 0.67. 
Ascore = 75.46 
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+2H-98
b2y1 b3 y2b4 b5 y3 y4b6 y5 b7
S G A A L S+80 K K
K K S+80 L A A G S
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 100 200 300 400 500 600 700 800
841,89 AMU, +2 H (Parent Error: 1800 ppm)
 
 
 
 
Close to precursor 
 
parent+2H-98
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
100%
362,5 365,0 367,5 370,0 372,5 375,0 377,5 380,0 382,5
841,89 AMU, +2 H (Parent Error: 1800 ppm)
Left of precursor 
 
 
y6+2H
b2y1
b3
y2
b4
A A L
K
m/z
R
el
at
iv
e 
In
te
ns
ity
0,00%
0,20%
0,40%
0,60%
0,80%
1,00%
125 150 175 200 225 250 275 300 325 350
841,89 AMU, +2 H (Parent Error: 1800 ppm)
 
 
 
Right of precursor 
 
x8-98+2H
y8-NH3-H2O+2H
y4-98
b6-98 y5-98
parent+2H-H2O
parent+2H-NH3
b5
y3
y4
b6
y5
b7
S+80 K
L A A
m/z
R
el
at
iv
e 
In
te
ns
ity
0,00%
0,25%
0,50%
0,75%
1,00%
1,25%
1,50%
400 425 450 475 500 525 550 575 600 625 650 675 700
841,89 AMU, +2 H (Parent Error: 1800 ppm)
 
 
Spectrum 6591.2240.2240.3.dta (charge state: +3) 
 
b2 b3 b4 b5 b6 b7 b8 b9 b10 b11 b12 b13
G Q V K E E G I N K pS E K R
y12 y10 y9 y8 y7 y5 y4 y3 y2 y1  
 
Sequest: XCorr = 3.92, dCn = 0.43. 
Ascore = Not available (only one possible phosphorylation site). 
 
The phosphorylation is located at the only possible phosphorylation site (no other S, T, Y within the peptide). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+3H+1-98
y1b2 b3
y2
b4y3
b5 y4 b6 y5b7 b8 b9 b10
G Q V K E E G I N K S+80 E K R
R K E S+80 K N I G E E K V Q G
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 200 400 600 800 1000 1200 1400 1600
1 682,42 AMU, +3 H (Parent Error: 950 ppm)
 
 
 
 
Close to precursor 
 
parent+3H+1-98
b5
S+80
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
500 520 540 580
1 682,42 AMU, +3 H (Parent Error: 950 ppm)
560
Left of precursor 
 
y8-98+2H
y4-NH3-98y8-H2O-H2O+2H y4-98
y8+2H
y8+2H+0
y9-H2O-98+2H
a10-NH3+2H
b4
y3
E
S+80
m/z
R
el
at
iv
e 
In
te
ns
ity
0,00%
0,50%
1,00%
1,50%
2,00%
2,50%
420 440 460 480 500 520
1 682,42 AMU, +3 H (Parent Error: 950 ppm)
 
 
 
 
Right of precursor 
 
b10-NH3+2H
y9-H2O-H2O+2H
b11-98+2H
b12-NH3-98+2H
y10+2H
y11-H2O-98+2H
b12-98+2H
y11-98+2H
b12+2H
b12+2H+1
a7
a7+1
b13-98+2H
y12+2H+1
y12+2H
b13+2H
b5
y4
b6
y5
b7
E G
K
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
1,0%
2,0%
3,0%
550 575 600 625 650 675 700 725 750
1 682,42 AMU, +3 H (Parent Error: 950 ppm)
 
 
 
Spectrum 6591.2712.2712.2.dta (charge state: +2) 
 
b2 b3 b4 b5 b6 b7 b8
K L pT V N P G T K
y8 y7 y6 y5 y4 y3 y2  
 
Sequest: XCorr = 2.45, dCn = 0.74. 
Ascore = 21.23. 
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
500,3?
y5-NH3
parent+2H-98
b2
y2 y3
y4
b3
y6
b5 b6 b7
y7
b8y8
K L T+80 V N P G T K
K T G P N V T+80 L K
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 200 400 600 800 1000
1 034,69 AMU, +2 H (Parent Error: -1800 ppm)
 
 
 
 
Close to precursor 
 
500,3?
y5-NH3
parent+2H-98
V
N
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
100%
440 460 480 500
1 034,69 AMU, +2 H (Parent Error: -1800 ppm)
Left of precursor 
 
c4-98+2H
b4-NH3+2Hb5-H2O-98+2H
a3-NH3-98
b5-NH3-NH3+2H
b3-H2O-98
y6+2H
b3-98
c6-98+2H
a6+2H
c7-98+2H
a7-NH3+2H
y4-NH3
y7-H2O+2H b4-98
b8-NH3-NH3+2H
a4-NH3-H2O
parent+2H-NH3-98
b2
y2
y3
y4
b3
T+80
G P N
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
8,0%
225 250 275 300 325 350 375 400 425 450
1 034,69 AMU, +2 H (Parent Error: -1800 ppm)
 
 
 
 
Right of precursor 
 
 
a5
a6-NH3+1
y7-98
y7+1
y8-98
y6
b5
b6
b7
y7
b8
y8
N P G T
V T+80 L
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
8,0%
10,0%
550 600 650 700 750 800 850 900
1 034,69 AMU, +2 H (Parent Error: -1800 ppm)
 
 
 
 
 
Supplementary mass spectrometric data: 
PARP-1,  
phosphorylated with Ca2+/calmodulin-dependent protein kinase-II (CaMK II) 
 
 
 
Spectrum 8170.2475.2475.2.dta (charge state: +2) 
 
b2 b3 b4 b5 b6 b7 b8
K V C pS T N D L K
y8 y7 y6 y5 y4 y3 y2  
 
Sequest: XCorr = 2.24, dCn1 = 0.08 (between 1st and 2nd best matches), dCn2 = 0.64 (between 2nd and 3rd best matches).  
Ascore = 0. 
 
Sequest’s second best match with XCorr = 2.05 is to the same peptide sequence but with an alternative phosphorylation site: 
KVCSpTNDLK.  
 
The very weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
y7+2H parent+2H-98
b2
y2
y3b3 y4
b4
y5 y6b6
b7
y7
b8y8
K V C+57 S+80 T N D L K
K L D N T S+80 C+57 V K
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 200 400 600 1000
1 144,08 AMU, +2 H (Parent Error: 500 ppm)
800
 
 
 
 
Close to precursor 
 
parent+2H-98
T
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
510 520 530 540
1 144,08 AMU, +2 H (Parent Error: 500 ppm)
Left of precursor 
 
y7+2H
b2
y2
y3 b3 y4
C+57 S+80
D N
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
225 250 275 300 325 350 375 400 425 450 475 500
1 144,08 AMU, +2 H (Parent Error: 500 ppm)
 
 
 
 
Right of precursor 
 
y5-H2O-H2O
b4+0
y7-196
b7-98
b7+1
parent+2H-H2O
b4
y5
y6
b6
b7
y7
b8 y8
T N D L
T S+80 C+57 V
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
15,0%
17,5%
600 700 800 1000
1 144,08 AMU, +2 H (Parent Error: 500 ppm)
900
 
Spectrum 8170.3518.3518.2.dta (charge state: +2) 
 
b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16
G G pS D D S S K D P I D V N Y E K
y16 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6 y5 y4 y3 y2  
 
Sequest: XCorr = 5.12, dCn = 0.12. 
Ascore = 23.27. 
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+2H+1-98
y2 b4 y3 b5 y4 b6
y5
b7 y6 b8 y7
b9 y8
b10 y9 b11 y10
b12
y11b13y12 b14y13 b15 b16
G G S+80 D D S S K D P I D V N Y E K
K E Y N V D I P D K S S D D S+80 G G
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750
1 906,65 AMU, +2 H (Parent Error: 990 ppm)
 
 
 
 
Close to precursor 
 
parent+2H+1-98
y7
b9
D
P
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
860 880 900 920 960
1 906,65 AMU, +2 H (Parent Error: 990 ppm)
940
Left of precursor 
 
y5+1
b8-98
y13+2H
y13+2H+1
y14+2H
b16-98+2H
y15-98+2H
y15-H2O+2Hy15-NH3+2H
a17-98+2H
y2
y5
b4
y3 b5
y4
b6 b7
y6 b8
y7
D D S S K D
Y N V D I
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
1,0%
2,0%
3,0%
300 400 500 600 800
1 906,65 AMU, +2 H (Parent Error: 990 ppm)
700
 
 
 
 
Right of precursor 
 
b9+1
y17-H2O-H2O+2H
y8+1
y8+2
y9+1
b12-98
b12+1
b12+2
b9
y8
b10
y9
b11
y10
b12
y11
b13
y12
b14
y13
b15 b16
P I D V N Y E
P D K S S D D S+80
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
1,0%
2,0%
3,0%
4,0%
1000 1200 1600
1 906,65 AMU, +2 H (Parent Error: 990 ppm)
1400
 
 
Spectrum 8170.3753.3753.2.dta (charge state: +2) 
 
b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16
G G pS D D pS S K D P I D V N Y E K
y16 y15 y14 y13 y12 y11 y9 y8 y7 y6 y5 y4 y3  
 
Sequest: XCorr = 5.04, dCn1 = 0.05 (between 1st and 2nd best matches), dCn2 = 0.13 (between 2nd and 3rd best matches).  
Ascore = 28.34 (first phosphorylation), 11.51 (second phosphorylation). 
 
Sequest’s second best match with XCorr = 4.79 is to the same peptide sequence but with an alternative phosphorylation site: 
GGpSDDSpSKDPIDVNYEK.  
 
The weak Ascore for the second phosphorylation indicates that, given the observed MS/MS spectrum, the phosphopeptide 
identified could either be Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+2H+1-196
parent+2H+1-98
y3 b5 y4
y5
b6 b7 y7b8
y8
b9
y9 b11 y11
b12
b13y12 b14 b15 b16
G G S+80 D D S+80 S K D P I D V N Y E K
K E Y N V D I P D K S S+80 D D S+80 G G
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1750
1 984,62 AMU, +2 H (Parent Error: -55 ppm)
1500
 
 
 
 
Close to precursor 
 
parent+2H+1-196
parent+2H+1-98
y7 b8
y8
b9
K D
P D
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
850 875 900 925 950 975 1000 1025
1 984,62 AMU, +2 H (Parent Error: -55 ppm)
 
Left of precursor 
 
b7+1
b7+2
y13+2H
y13+2H+1
b9-196
y14+2H
b16-98+2Hz15-98+2H
y15-98+2H
parent+2H-NH3-1
y3
b5
y4
y5
b6 b7
y7
b8
D S+80 S K
N V D I
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
1,0%
2,0%
3,0%
4,0%
500 600 800
1 984,62 AMU, +2 H (Parent Error: -55 ppm)
700
 
 
 
 
Right of precursor 
 
b9-NH3-H2O
y8+1
y9+1
b12-98
b13-196
b12+1
y8
b9
y9
b11
y11
b12
b13 y12
b14
b15 b16
P I D V N Y E
D K S S+80 D D S+80
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
1000 1200 1400 1800
1 984,62 AMU, +2 H (Parent Error: -55 ppm)
1600
 
 
 
 
 
Supplementary mass spectrometric data: 
PARP-1,  
phosphorylated with C-Jun N-Terminal Kinase 1 (JNK1)  
 
 
 
Spectrum Ingel8474.12185.12185.3.dta (charge state: +3) 
 
b2 b3 b4 b5 b6 b7 b8 b9 b10 b11 b13 b14 b15
K V C pS T N D L K E L L I F N K
y15 y14 y13 y12 y10 y9 y8 y7 y6 y5 y4 y3 y2  
 
Sequest: XCorr = 5.29, dCn1 = 0.06 (between 1st and 2nd best matches), dCn2 = 0.85 (between 2nd and 3rd best matches).  
Ascore = 13.49. 
 
Sequest’s second best matches with XCorr = 4.97 is to the same peptide sequence but with an alternative phosphorylation site:  
 
KVCSpTNDLKELLIFNK 
 
The weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
y9+2H
parent+3H+1-98
b2y2 b3
y3 y4
b4 b5
y6b6
y7
b7
b8
y8 y9b9
K V C+57 S+80 T N D L K E L L I F N
K N F I L L E K L D N T S+80 C+57 V
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750
2 002,70 AMU, +3 H (Parent Error: 850 ppm)
 
 
 
 
Close to precursor 
 
parent+3H+1-98
b5
T
L
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
600 620 640 680
2 002,70 AMU, +3 H (Parent Error: 850 ppm)
660
Left of precursor 
 
y9+2H
y9+2H+0
b2
y2
b3
y3
y4
b4
C+57 S+80
N F I L
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
15,0%
17,5%
20,0%
200 250 300 350 400 450 500 550 600
2 002,70 AMU, +3 H (Parent Error: 850 ppm)
 
 
 
 
Right of precursor 
 
y12+2H
a6
y6+1
y6+2
b7-98
b13+2H
y13+2H
y7+1b15-98+2H
b7+1y14+2H
b8-98
b15+2H
y15+2H+1
y15+2H
b7
b8
b5
y6
b6
y7
y8
y9
b9
N D L K
L E K L
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
700 800 900 1100
2 002,70 AMU, +3 H (Parent Error: 850 ppm)
1000
Spectrum Ingel8474.9821.9821.2.dta (charge state: +2) 
 
b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16
G G pS D D S S K D P I D V N Y E K
y16 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6 y5 y4 y3 y2  
 
Sequest: XCorr = 5.43, dCn = 0.99. 
Ascore = 32.37.  
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
parent+2H-NH3-98
parent+2H-98
parent+2H+1-98
y2 b4 y3 b5
y4
y5
b7
y6 b8 y7
b9
y8
y9
b11 y10
b12
y11b13y12 b14y13 b15 b16
G G S+80 D D S S K D P I D V N Y E K
K E Y N V D I P D K S S D D S+80 G G
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750
1 905,46 AMU, +2 H (Parent Error: 360 ppm)
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+2H-NH3-98
parent+2H-98
parent+2H+1-98
y2 b4 y3 b5
y4
y5
b7
y6 b8 y7
b9
y8
y9
b11 y10
b12
y11b13y12 b14y13 b15 b16
G G S+80 D D S S K D P I D V N Y E K
K E Y N V D I P D K S S D D S+80 G G
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750
1 905,46 AMU, +2 H (Parent Error: 360 ppm)
 
 
 
 
Close to precursor 
 
parent+2H-NH3-98
parent+2H-98
parent+2H+1-98
y7
b9
P
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
880 890 900 910 930
1 905,46 AMU, +2 H (Parent Error: 360 ppm)
920
Left of precursor 
 
y5+1
y13+2H
y6+1
y14+2Hb9-98
y15-98+2H
y15-H2O+2H
y15-NH3+2H
a17-98+2H
y2
y5
b4
y3 b5
y4
b7
y6
b8
y7
D D S S K D
Y N V D I
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
300 400 500 600 800
1 905,46 AMU, +2 H (Parent Error: 360 ppm)
700
 
 
 
 
Right of precursor 
 
b9+1y17-H2O-H2O+2H
y8+1
y9+1
b12-98
b12+1
y8
b9
y9
b11
y10
b12
y11
b13
y12
b14
y13
b15 b16
P I D V N Y E
P D K S S D D S+80
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
8,0%
10,0%
1000 1100 1200 1300 1400 1500 1600 1700
1 905,46 AMU, +2 H (Parent Error: 360 ppm)
 
  
 
 
 
Supplementary mass spectrometric data: 
PARP-1,  
phosphorylated with Cyclin-dependent kinase-5 (CDK5) 
 
 
 
 
 
Spectrum Ingel8473.10404.10404.2.dta (charge state: +2) 
 
b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16
G G pS D D S S K D P I D V N Y E K
y16 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6 y5 y4 y3 y2  
 
Sequest: XCorr = 4.56, dCn1 = 0.10 (between 1st and 2nd best matches), dCn2 = 0.13 (between 2nd and 3rd best matches), dCn2 = 
0.91 (between 3rd and 4th best matches).  
Ascore = 13.49. 
 
Sequest’s second and third best matches with XCorr = 4.12 and XCorr = 3.96 respectively are to the same peptide sequence but 
with alternative phosphorylation sites:  
 
GGSDDpSSKDPIDVNYEK 
 
GGpSDDSpSKDPIDVNYEK 
 
The very weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first, second or third best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+2H+1-98
parent+2H+3-98
y2 b4 y3 b5 y4 b6
y5
b7 y6 b8 y7
b9
y8
b10 y9 b11 y10b12 y11b13y12 b14 b15 b16
G G S+80 D D S S K D P I D V N Y E K
K E Y N V D I P D K S S D D S+80 G G
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750
1 906,41 AMU, +2 H (Parent Error: 860 ppm)
 
 
 
 
Close to precursor 
 
parent+2H+1-98
parent+2H+3-98
y7
b9
D
P
m/z
R
el
at
iv
e 
In
te
ns
ity
100%
0%
20%
40%
60%
80%
870 880 890 900 910 920 930 940
1 906,41 AMU, +2 H (Parent Error: 860 ppm)
Left of precursor 
 
y5+1
y13+2H
y6+1a8-NH3
y14+2H
b16-98+2H
y15-98+2H
y15-H2O+2H
y15-NH3+2H
a17-98+2H
y2
y5
b4
y3
b5
y4
b6 b7
y6
b8
y7
D D S S K D
Y N V D I
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
1,0%
2,0%
3,0%
4,0%
300 400 500 600 800
1 906,41 AMU, +2 H (Parent Error: 860 ppm)
700
 
 
 
 
Right of precursor 
 
b9+1
b17-NH3-H2O+2H
y8+1
b12-98
b12+1
y8
b9
b10
y9
b11
y10
b12
y11
b13
y12
b14 b15 b16
P I D V N Y E
P D K S S D D S+80
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
1000 1100 1200 1300 1400 1500 1600 1700
1 906,41 AMU, +2 H (Parent Error: 860 ppm)
 
  
 
  
Supplementary mass spectrometric data: 
PARG, Casein kinase II-phosphorylated 
 
 
 
Spectrum 7806.3163.3163.3.dta (charge state: +3) 
 
b5 b6 b7 b8 b9 b10 b11 b12 b16 b18 b19 b20 b21 b22 b23 b24 b25
S P Q N D D H pS D pT D S E E N R D N Q Q F L T T V K
y24 y23 y22 y21 y20 y19 y18 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6 y5 y4  
 
Sequest: XCorr = 4.93, dCn = 0.11. 
Ascore = 23.16 (first phosphorylation), 29.85 (second phosphorylation).  
 
Both phosphorylation sites are localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
parent+3H+2-196
parent+3H-NH3-98
parent+3H+3-98
y4 b5y5 b6y6 b7y7
b8
b9y y10b10 y11b11 b12
S P Q N D D H S+80 D T+80 D S E E N R D N Q Q F L T T V
K V T T L F Q Q N D R N E E S D T+80 D S+80 H D D N Q P
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000
3 181,17 AMU, +3 H (Parent Error: 610 ppm)
 
 
 
 
Close to precursor 
 
parent+3H+2-196
parent+3H-NH3-98
parent+3H+3-98
b9 y9
D
N
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
980 1000 1020 1040 1060 1080
3 181,17 AMU, +3 H (Parent Error: 610 ppm)
Left of precursor 
 
y15+2H
y15+2H+1
a17-98+2H
internal PQNDD
b16+2H
parent+3H-NH3
y4
b5
y5
b6
y6
b7
y7
b8
D D H S+80
T L F Q Q
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
8,0%
10,0%
400 500 600 700 900
3 181,17 AMU, +3 H (Parent Error: 610 ppm)
800
 
 
 
 
Right of precursor 
 
y18+2Hy19-NH3-98+2H
y19-98+2H
c20-196+2H
a19+2H
a19+2H+1
y20-196+2H
b19+2H
y20-98+2H
a20-NH3+2H
a20-NH3+2H+1
a20+2H
y20-NH3+2H
b21-98+2H
y20+2H
y20+2H+1
y21-98+2Hb11-98
b21+2H
b21+2H+1
b22-98+2H
y21+2H
y21+2H+1
y22-98+2H
b22-NH3+2H
b22-NH3+2H+1b23-98+2H
b11+1
y22+2H
y22+2H+1
y23-98+2H
a23-NH3-NH3+2Hb25-H2O-196+2H
y23-NH3+2H
y23+2H
b12+1
b25-NH3+2H
b25+2H
b9y9
y10
b10
y11
b11
b12
T+80 D S
D R N
m/z
R
el
at
iv
e 
In
te
ns
ity
0,00%
0,50%
1,00%
1,50%
2,00%
2,50%
1100 1200 1300 1500
3 181,17 AMU, +3 H (Parent Error: 610 ppm)
1400
 
 
Spectrum 7806.3181.3181.3.dta (charge state: +3) 
 
b3 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16 b17 b19 b20 b21 b22 b23 b24 b26
Q E S C L G N S P P F E K E pS E P E S P M D V D N S K
y25 y23 y22 y20 y19 y18 y17 y16 y15 y14 y13 y12 y11 y10 y9 y8 y7 y6 y5 y4  
 
Sequest: XCorr = 4.97, dCn = 0.10. 
Ascore = 26.34.  
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
 
a18-98+2H
y18-H2O-128+2Hy19+2H
parent+3H-NH3-98
parent+3H+1-98
parent+3H+3-98
y4 y5
b5
y6 y7b8
y8
y9
b11
y11
b12
y12 y13
Q E S C+57 L G N S P P F E K E S+80 E P E S P M+16 D V D N S K
K S N D V D M+16 P S E P E S+80 E K E F P P S N G L C+57 S E Q
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000
3 134,63 AMU, +3 H (Parent Error: 760 ppm)
 
 
 
Close to precursor 
 
a18-98+2H
y18-H2O-128+2H
parent+3H-NH3-98
parent+3H+1-98
parent+3H+3-98
y9
P
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
100%
990 1000 1010 1020 1030
3 134,63 AMU, +3 H (Parent Error: 760 ppm)
Left of precursor 
 
b8-H2O
b8-NH3
b8-NH3+1
y15+2H
b16+2H
b17+2H+1
a18-98+2H
parent+3H-1
y4
y5
b5
y6 y7
b8
y8
C+57 L G N S P
D V D M+16 P S
m/z
R
el
at
iv
e 
In
te
ns
ity
40%
0%
10%
20%
30%
400 500 600 700 800 900 1000
3 134,63 AMU, +3 H (Parent Error: 760 ppm)
 
 
 
 
Right of precursor 
 
a10-NH3+1
a10-NH3+2
y18+2H
y18+2H+1
y19+2H+1
y19+2H
y20+2H
y22-98+2H
y22+2Hy22+2H+1
y25+2H
parent+3H-H2O-64
parent+3H-NH3-64
b11
y11
b12
y12 y13
P F E K E S+80 E
E P E S+80 E K E
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
10%
20%
30%
40%
1200 1400 1800
3 134,63 AMU, +3 H (Parent Error: 760 ppm)
1600
 
 
Spectrum 7806.4250.4250.3.dta (charge state: +3) 
 
b8 b9 b11 b15 b16 b17 b18 b19 b25 b29 b32 b34
S C D P G E D C A S C Q Q D E I D V V P E S P L pS D V G S E D V G T G P K
y34 y31 y28 y24 y21 y19 y18 y17 y16 y15 y14 y13 y12 y10  
 
Sequest: XCorr = 2.72, dCn1 = 0.03 (between 1st and 2nd best matches), dCn2 = 0.11 (between 2nd and 3rd best matches).  
Ascore = 0. 
 
Sequest’s second best match with XCorr = 2.63 is to the same peptide sequence but with an alternative phosphorylation site: 
SCDPGEDCASCQQDEIDVVPEpSPLSDVGSEDVGTGPK.  
 
The very weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
y17+2H
b16+2H
b16+2H+1
y19+2H
y10
y12 y14
y15
y16
b15y17
y18
b16
y19
S C+57 D P G E D C+57 A S C+57 Q Q D E I D V V P E S P L S+80 D V G S E D V G T G P K
K P G T G V D E S G V D S+80 L P S E P V V D I E D Q Q C+57 S A C+57 D E G P D C+57 S
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 500 1000 1500 2000 2500 3000 3500 4000
4 017,28 AMU, +3 H (Parent Error: 670 ppm)
 
 
 
 
Close to precursor 
 
y24+2H
y13-NH3-H2O
y13-H2O
y13-NH3
a24-NH3-H2O+2H
y25-H2O+2H
a12-H2O
a12-NH3
parent+3H+1-98
parent+3H+3-98
Q
S+80
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,0%
4,0%
6,0%
1240 1260 1280 1300 1320 1340 1360 1380
4 017,28 AMU, +3 H (Parent Error: 670 ppm)
Left of precursor 
 
y17+2H
b16+2H
b16+2H+1
y19+2H
y10
y12
C+57 A S C+57
S G V D
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
100%
800 900 1000 1100 1200
4 017,28 AMU, +3 H (Parent Error: 670 ppm)
 
 
 
 
Right of precursor 
 
a25-NH3+2H
y15+1
b29-NH3+2H
x31-196+2H
b29+2H+1
y30-NH3+2H
b30-NH3+2H
y31-NH3+2H
y31+2H
a32-NH3+2Hy3 -NH3-NH3+2H
b32-NH3+2H
b32+2H
a16-NH3-H2O
a35-NH3-98+2H
b34-NH3+2H
y18+1
b34+2H
b35-NH3+2H
y18
y14
y15
y16
b15
y17
b16
y19
Q D E I D
L P S E P V
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
1400 1500 1600 1700 1900
4 017,28 AMU, +3 H (Parent Error: 670 ppm)
1800
 
 
Spectrum 7806.2578.2578.3.dta (charge state: +3) 
 
b3 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16 b17 b19 b20 b23 b24 b25 b26 b27 b29 b32
N S C Q D pS E A D E E T S P G F D E Q E D G S S S Q T A N K P S R
y32 y31 y25 y24 y21 y20 y19 y18 y16 y15 y14 y13 y12 y11 y10 y9 y7 y6 y5 y4  
 
Sequest: XCorr = 6.29, dCn = 0.14.  
Ascore = 23.35. 
 
Phosphorylation site is localized with ≥ 99% certainty as Ascore ≥ 20 (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
y20+2H+1
y20+2H
y21+2H+1y21+2H
parent+3H-NH3-98
parent+3H+1-98
b3 y4 y5b5y6 b6 b8y9 y10
b9
y11
y13
b11
b12
b13
y15
b14b15 b16 b17
N S C+57 Q D S+80 E A D E E T S P G F D E Q E D G S S S Q T A N K P S R
R S P K N A T Q S S S G D E Q E D F G P S T E E D A E S+80 D Q C+57 S N
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 500 1000 1500 2000 2500 3000 3500
3 669,51 AMU, +3 H (Parent Error: 300 ppm)
 
 
 
 
Close to precursor 
 
parent+3H-NH3-98
parent+3H+1-98
y11
E
G
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
1120 1140 1160 1180 1200 1220 1240 1260
3 669,51 AMU, +3 H (Parent Error: 300 ppm)
Left of precursor 
 
y20+2H+1
y20+2H
y21+2H+1y21+2H
b3 y4 y5b5 y6 b6 b8y9 y10
b9
y11
Q D S+80 E A D E
P K N A T Q S S S
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
400 600 1000
3 669,51 AMU, +3 H (Parent Error: 300 ppm)
800
 
 
 
 
Right of precursor 
 
b10-NH3
b22-98+2H
b21-NH3-H2O+2H
b11-98
a23-NH3+2H
a23+2H
a23+2H+1
y24+2H+1
y24+2H
a24+2H
b12-NH3-98
b24+2H
y25+2H+1
y25+2H
b25+2H
b25+2H+1
b26-98+2H
b13-H2O-98
a12
a26+2H
a26+2H+1
b12+1
y28-98+2H
a27+2H
x28-98+2H
b13-NH3-H2O
b13-H2O
b13-NH3
b13+1
y29-98+2H
y13
b11
b12
b13
y15
b14
b15 b16 b17
E T S P G F D E
D E Q E D F G
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
15,0%
1200 1300 1400 1500 1600 1700 1800 1900 2000
3 669,51 AMU, +3 H (Parent Error: 300 ppm)
 
Spectrum 7806.4157.4157.3.dta (charge state: +3) 
 
b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16 b17 b21
L Y P F I Y H A V E S C A E pT A D H S G Q R
y21 y20 y19 y18 y17 y16 y15 y13 y12 y11 y10 y9 y8 y7 y6 y5 y4  
 
Sequest: XCorr = 3.97, dCn1 = 0.05 (between 1st and 2nd best matches), dCn2 = 0.10 (between 2nd and 3rd best matches).  
 
Ascore = 7.65. 
 
Sequest’s second best match with XCorr = 3.76 is to the same peptide sequence but with an alternative phosphorylation site: 
LYPFIYHAVEpSCAEpTADHSGQR.  
 
The weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first or second best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
785,8?
786,5?
y7-NH3
parent+3H+1-98
b4
y5
b5 y6 y7b6 b7
y8
y9 b10 b11
L Y P F I Y H A V E S C+57 A E T+80 A D H S G Q R
R Q G S H D A T+80 E A C+57 S E V A H Y I F P Y L
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
0 250 500 750 1000 1250 1500 1750 2000 2250 2500
2 632,74 AMU, +3 H (Parent Error: 990 ppm)
 
 
 
 
Close to precursor 
 
parent+3H+1-98
H
T+80
100%
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
820 840 880
2 632,74 AMU, +3 H (Parent Error: 990 ppm)
860
Left of precursor 
 
785,8?
786,5?
y7-NH3
b4
y5
b5 y6
y7 b6
I Y
H D A
m/z
R
el
at
iv
e 
In
te
ns
ity
0%
20%
40%
60%
80%
525 550 575 600 625 650 675 700 725 750 775 800 825
2 632,74 AMU, +3 H (Parent Error: 990 ppm)
 
 
 
 
Right of precursor 
 
y16+2H
y17-98+2H
x18-196+2H
y17+2H
b8+1
b17+2H
y18+2H
b9+1
y20-98+2H
y19+2H
a20+2H
y20+2H
y20+2H+1
y20+2H+2
b7
y8
y9 b10
b11
A V E S C+57
E A C+57 S
m/z
R
el
at
iv
e 
In
te
ns
ity
0,0%
2,5%
5,0%
7,5%
10,0%
12,5%
900 1000 1100 1200 1400
2 632,74 AMU, +3 H (Parent Error: 990 ppm)
1300
 
 
Spectrum 7806.4498.4498.3.dta (charge state: +3) 
 
b6 b7 b8 b11 b12 b13 b14 b15 b16 b21 b23 b24 b25 b26
H T E Q L L E S E P Q pT V T L V P E Q F S N A N I D R
y23 y17 y16 y14 y12 y11 y10 y8 y6 y5 y4  
 
Sequest: XCorr = 3.50, dCn1 = 0.00 (between 1st and 2nd best matches), dCn2 = 0.01 (between 2nd and 3rd), dCn3 = 0.08 (between 
3rd and 4th).  
 
Ascore = 5.06. 
 
Sequest’s second and third best matches with XCorr = 3.50 and XCorr = 3.25 respectively are to the same peptide sequence but 
with alternative phosphorylation sites:  
 
HTEQLLEpSEPQTVTLVPEQFSNANIDR 
 
HpTEQLLESEPQTVTLVPEQFSNANIDR 
 
The weak Ascore indicates that, given the observed MS/MS spectrum, the phosphopeptide identified could either be 
Sequest’s first, second or third best match (Nat Biotechnol. 2006;24(10):1285-92). 
 
 
MS/MS spectrum’s fragmentation table 
 
 
 
MS/MS spectrum 
 
 
 
Full-range  
 
b15-NH3+2H
b15+2H
b15+2H+1
b16+2H
a17+2H+1
y11+1
y4 y5 y6b6
b7
b8
y10
y11
b11
y12
b13
y14
b15
b16
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